Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
elements	I-DNA
.	O

Ten	O
mutants	O
of	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
SIVmac239	O
bearing	O
deletions	O
(	O
delta	O
)	O
or	O
substitutions	O
(	O
subst	O
)	O
in	O
the	O
NF-kappaB	B-DNA
and/or	O
Sp1	B-DNA
binding	I-DNA
elements	I-DNA
were	O
created	O
,	O
and	O
the	O
replicative	O
capacities	O
of	O
the	O
mutants	O
were	O
analyzed	O
.	O

All	O
mutants	O
,	O
including	O
one	O
extensively	O
mutagenized	O
strain	O
entirely	O
missing	O
the	O
NF-kappaB	B-DNA
and	I-DNA
four	I-DNA
Spl	I-DNA
binding	I-DNA
elements	I-DNA
,	O
replicated	O
with	O
wild-type	O
kinetics	O
and	O
to	O
a	O
wild-type	O
level	O
in	O
peripheral	B-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cell	I-cell_line
cultures	I-cell_line
in	O
50	O
to	O
100	O
%	O
of	O
the	O
experiments	O
.	O

One	O
group	O
of	O
mutants	O
replicated	O
very	O
similarly	O
to	O
SIVmac239	O
in	O
kinetics	O
and	O
yield	O
in	O
CEMxl74	B-cell_line
cells	I-cell_line
(	O
2x	O
NFKappaB	B-protein
>	O
or	O
=	O
SlVmac239	B-protein
approximately	O
deltaNFkappaB	B-protein
approximately	O
deltaSpl234	B-protein
approximately	O
substNFkappaB	B-protein
approximately	O
substSpl2	B-protein
approximately	O
substSp23	B-protein
)	O
,	O
while	O
a	O
second	O
group	O
replicated	O
with	O
delayed	O
or	O
slightly	O
delayed	O
kinetics	O
in	O
CEMxl74	B-cell_line
cells	I-cell_line
(	O
SIVmac239	O
>	O
substSp34	B-protein
>	O
deltaNFkappaBdeltaSpl234	B-protein
approximately	O
deltaNFkappaBdeltaSp1	B-protein
>	O
substSpl234	B-protein
)	O
.	O

Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	B-DNA
and	I-DNA
R	I-DNA
regions	I-DNA
of	O
proviral	B-DNA
DNA	I-DNA
from	O
CEMxl74	B-cell_line
cells	I-cell_line
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
mutants	O
of	O
SIVmacMER	O
(	O
a	O
macrophage-competent	O
derivative	O
of	O
SIVmac239	O
)	O
were	O
tested	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cell	I-cell_type
and	O
CEMx174	B-cell_line
cultures	I-cell_line
.	O

However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	B-cell_type
rhesus	I-cell_type
monkey	I-cell_type
alveolar	I-cell_type
macrophages	I-cell_type
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	B-protein
approximately	O
substNFkappaB	B-protein
>	O
deltaNFkappaB	B-protein
>	O
deltaNFkappaB	B-protein
deltaSpl234	B-protein
approximately	O
deltaNFkappaBdeltaSpl	B-protein
>	O
deltaSpl234	B-protein
approximately	O
substSpl2	B-protein
>	O
substSp23	B-protein
approximately	O
substSp34	B-protein
approximately	O
substSpl234	B-protein
>	O
or	O
=	O
SIVmac239	O
)	O
.	O

Thus	O
,	O
changes	O
in	O
the	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
had	O
the	O
most	O
dramatic	O
effects	O
on	O
SIVmac	O
replication	O
in	O
primary	B-cell_line
macrophage	I-cell_line
cultures	I-cell_line
.	O

Analysis	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
-driven	O
secreted	O
alkaline	B-protein
phosphatase	I-protein
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
possesses	O
an	O
enhancer	B-DNA
region	I-DNA
just	O
upstream	O
of	O
the	O
NF-kappaB	B-DNA
element	I-DNA
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF-kappaB	B-DNA
and	I-DNA
Sp1	I-DNA
sites	I-DNA
.	O

This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	B-protein
.	O

In	O
addition	O
,	O
the	O
SIV	B-DNA
TATA	I-DNA
box	I-DNA
was	O
shown	O
to	O
be	O
stronger	O
than	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Therefore	O
,	O
the	O
surprisingly	O
high	O
replicative	O
capacity	O
of	O
NF-kappaB	O
and	O
Sp1	O
binding	O
site	O
mutants	O
of	O
SIVmac	O
is	O
due	O
to	O
unique	O
features	O
or	O
the	O
enhancer/promoter	B-DNA
region	I-DNA
.	O

JournaL	NULL
or	NULL
VirRoLoGYy	NULL
,	NULL
May	NULL
1996	NULL
,	NULL
p.	NULL
3118-3126	NULL
0022-538	NULL
Copyright	NULL
©	NULL
1996	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

70	NULL
,	NULL
No	NULL
.	NULL

5	NULL
Efficient	NULL
Transcription	NULL
and	NULL
Replication	NULL
of	NULL
Simian	NULL
Immunodeficiency	NULL
Virus	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
Binding	NULL
Elements	NULL
PETR	NULL
O.	NULL
ILYINSKII	NULL
anp	NULL
RONALD	NULL
C.	NULL
DESROSIERS®*	NULL
New	NULL
England	NULL
Regional	NULL
Primate	NULL
Research	NULL
Center	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Southborough	NULL
,	NULL
Massachusetts	NULL
01772-9102	NULL
Received	NULL
8	NULL
November	NULL
1995/Accepted	NULL
12	NULL
February	NULL
1996	NULL
Ten	NULL
mutants	NULL
of	NULL
the	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
SIV	NULL
)	NULL
SIVmac239	NULL
bearing	NULL
deletions	NULL
(	NULL
A	NULL
)	NULL
or	NULL
substitutions	NULL
(	NULL
subst	NULL
)	NULL
in	NULL
the	NULL
NF-B	NULL
and/or	NULL
Sp1	NULL
binding	NULL
elements	NULL
were	NULL
created	NULL
,	NULL
and	NULL
the	NULL
replicative	NULL
capacities	NULL
of	NULL
the	NULL
mutants	NULL
were	NULL
analyzed	NULL
.	NULL

All	NULL
mutants	NULL
,	NULL
including	NULL
one	NULL
extensively	NULL
mutagenized	NULL
strain	NULL
entirely	NULL
missing	NULL
the	NULL
NF-B	NULL
and	NULL
four	NULL
Sp1	NULL
binding	NULL
elements	NULL
,	NULL
replicated	NULL
with	NULL
wild-type	NULL
kinetics	NULL
and	NULL
to	NULL
a	NULL
wild-type	NULL
level	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
cultures	NULL
in	NULL
50	NULL
to	NULL
100	NULL
%	NULL
of	NULL
the	NULL
experiments	NULL
.	NULL

One	NULL
group	NULL
of	NULL
mutants	NULL
replicated	NULL
very	NULL
similarly	NULL
to	NULL
S	NULL
[	NULL
Vmac239	NULL
in	NULL
kinetics	NULL
and	NULL
yield	NULL
in	NULL
CEMx174	NULL
cells	NULL
substSp12~substSp23	NULL
)	NULL
,	NULL
while	NULL
a	NULL
second	NULL
group	NULL
replicated	NULL
with	NULL
delayed	NULL
or	NULL
slightly	NULL
delayed	NULL
kinetics	NULL
in	NULL
CEMx174	NULL
cells	NULL
(	NULL
STVmac239	NULL
>	NULL
substSp34	NULL
>	NULL
ANFKBASp1234~ANFrBASp1	NULL
>	NULL
substSp1234	NULL
)	NULL
.	NULL

Reversions	NULL
or	NULL
additional	NULL
mutations	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
the	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
of	NULL
proviral	NULL
DNA	NULL
from	NULL
CEMx174	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
S	NULL
[	NULL
Vmac239	NULL
mutants	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
mutants	NULL
of	NULL
SIVmacMER	NULL
(	NULL
a	NULL
macrophage-competent	NULL
derivative	NULL
of	NULL
SIVmac239	NULL
)	NULL
were	NULL
tested	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
and	NULL
CEMx174	NULL
cultures	NULL
.	NULL

However	NULL
,	NULL
the	NULL
growth	NULL
of	NULL
most	NULL
mutated	NULL
viruses	NULL
was	NULL
suppressed	NULL
in	NULL
primary	NULL
rhesus	NULL
monkey	NULL
alveolar	NULL
macrophages	NULL
(	NULL
STVmacMER~2xNFKkB~substNFKB	NULL
>	NULL
ANFKB	NULL
>	NULL
>	NULL
ASp1234~substSp12	NULL
>	NULL
substSp23~substSp34~substSp1234z	NULL
>	NULL
SIVmac239	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
changes	NULL
in	NULL
the	NULL
Spl	NULL
binding	NULL
sites	NULL
had	NULL
the	NULL
most	NULL
dramatic	NULL
effects	NULL
on	NULL
SIVmac	NULL
replication	NULL
in	NULL
primary	NULL
macrophage	NULL
cultures	NULL
.	NULL

Analysis	NULL
of	NULL
long	NULL
terminal	NULL
repeat-driven	NULL
secreted	NULL
alkaline	NULL
phosphatase	NULL
activity	NULL
in	NULL
transient	NULL
assays	NULL
showed	NULL
that	NULL
,	NULL
unlike	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
,	NULL
the	NULL
SIV	NULL
long	NULL
terminal	NULL
repeat	NULL
possesses	NULL
an	NULL
enhancer	NULL
region	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
NF-KB	NULL
element	NULL
which	NULL
maintains	NULL
significant	NULL
levels	NULL
of	NULL
basal	NULL
transcription	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
NF-KB	NULL
and	NULL
Spl	NULL
sites	NULL
.	NULL

This	NULL
region	NULL
is	NULL
responsive	NULL
to	NULL
transactivation	NULL
by	NULL
Tat	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
SIV	NULL
TATA	NULL
box	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
stronger	NULL
than	NULL
that	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
surprisingly	NULL
high	NULL
replicative	NULL
capacity	NULL
of	NULL
NF-KB	NULL
and	NULL
Spl	NULL
binding	NULL
site	NULL
mutants	NULL
of	NULL
SIVmac	NULL
is	NULL
due	NULL
to	NULL
unique	NULL
features	NULL
of	NULL
the	NULL
enhancer/promoter	NULL
region	NULL
.	NULL

The	NULL
transcription	NULL
of	NULL
retroviruses	NULL
is	NULL
directed	NULL
by	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeats	NULL
(	NULL
LTRs	NULL
)	NULL
,	NULL
which	NULL
are	NULL
located	NULL
at	NULL
the	NULL
ends	NULL
of	NULL
proviral	NULL
DNA	NULL
.	NULL

Each	NULL
LTR	NULL
consists	NULL
of	NULL
three	NULL
regions	NULL
:	NULL
U3	NULL
,	NULL
R	NULL
,	NULL
and	NULL
US	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Major	NULL
transcriptional	NULL
control	NULL
elements	NULL
(	NULL
TCEs	NULL
)	NULL
reside	NULL
within	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
retroviral	NULL
LTRs	NULL
.	NULL

Efficient	NULL
transcription	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
promoter	NULL
,	NULL
binding	NULL
sites	NULL
for	NULL
transcription	NULL
factors	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
,	NULL
and	NULL
the	NULL
Tat-responsive	NULL
region	NULL
(	NULL
TAR	NULL
)	NULL
(	NULL
10	NULL
,	NULL
11	NULL
,	NULL
14	NULL
,	NULL
18	NULL
,	NULL
19	NULL
,	NULL
21	NULL
,	NULL
30	NULL
,	NULL
38	NULL
[	NULL
reviewed	NULL
in	NULL
references	NULL
8	NULL
and	NULL
12	NULL
]	NULL
)	NULL
.	NULL

HIV-1	NULL
contains	NULL
three	NULL
Spl	NULL
and	NULL
two	NULL
binding	NULL
sites	NULL
upstream	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
.	NULL

Their	NULL
elimination	NULL
results	NULL
in	NULL
essentially	NULL
total	NULL
inactivation	NULL
of	NULL
the	NULL
provirus	NULL
(	NULL
11	NULL
,	NULL
16	NULL
,	NULL
23	NULL
,	NULL
39	NULL
)	NULL
.	NULL

While	NULL
a	NULL
number	NULL
of	NULL
other	NULL
transcription	NULL
factors	NULL
have	NULL
been	NULL
linked	NULL
to	NULL
various	NULL
parts	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
12	NULL
,	NULL
33	NULL
,	NULL
40	NULL
)	NULL
,	NULL
none	NULL
of	NULL
them	NULL
can	NULL
compensate	NULL
for	NULL
the	NULL
loss	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Spl	NULL
binding	NULL
sites	NULL
.	NULL

The	NULL
HIV-1	NULL
TCEs	NULL
appear	NULL
to	NULL
possess	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
functional	NULL
redundancy	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Mutated	NULL
HIV-1	NULL
missing	NULL
one	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
all	NULL
Spl	NULL
sites	NULL
is	NULL
still	NULL
capable	NULL
of	NULL
efficient	NULL
replication	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
stimulated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
23	NULL
,	NULL
39	NULL
)	NULL
.	NULL

The	NULL
latter	NULL
findings	NULL
are	NULL
somewhat	NULL
different	NULL
from	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
reporter	NULL
gene	NULL
constructs	NULL
in	NULL
transient	NULL
assays	NULL
in	NULL
which	NULL
the	NULL
loss	NULL
of	NULL
one	NULL
of	NULL
the	NULL
or	NULL
Sp1	NULL
sites	NULL
was	NULL
readily	NULL
detectable	NULL
and	NULL
in	NULL
which	NULL
the	NULL
elimination	NULL
of	NULL
two	NULL
or	NULL
more	NULL
sites	NULL
had	NULL
a	NULL
profound	NULL
effect	NULL
on	NULL
LTR-driven	NULL
transcription	NULL
(	NULL
1	NULL
,	NULL
3	NULL
,	NULL
15	NULL
,	NULL
25	NULL
,	NULL
30	NULL
,	NULL
35	NULL
)	NULL
.	NULL

*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
New	NULL
England	NULL
Regional	NULL
Primate	NULL
Research	NULL
Center	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
One	NULL
Pine	NULL
Hill	NULL
Dr.	NULL
,	NULL
Box	NULL
9102	NULL
,	NULL
Southborough	NULL
,	NULL
MA	NULL
01772-9102	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
508	NULL
)	NULL
624-8042	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
508	NULL
)	NULL
624-8190	NULL
.	NULL

3118	NULL
While	NULL
numerous	NULL
studies	NULL
have	NULL
focused	NULL
on	NULL
the	NULL
relative	NULL
importance	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
for	NULL
HIV-1	NULL
replication	NULL
in	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
activated	NULL
lymphocytes	NULL
,	NULL
we	NULL
are	NULL
aware	NULL
of	NULL
only	NULL
a	NULL
single	NULL
study	NULL
which	NULL
has	NULL
addressed	NULL
a	NULL
role	NULL
in	NULL
primary	NULL
macrophages	NULL
.	NULL

Moses	NULL
et	NULL
al	NULL
.	NULL

(	NULL
29	NULL
)	NULL
used	NULL
transfection	NULL
assays	NULL
to	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
HIV-1	NULL
enhancer	NULL
mutations	NULL
on	NULL
expression	NULL
in	NULL
primary	NULL
monocytes/macrophages	NULL
.	NULL

Sp1	NULL
elements	NULL
had	NULL
the	NULL
greatest	NULL
effect	NULL
in	NULL
unstimulated	NULL
monocytes/macrophages	NULL
,	NULL
but	NULL
other	NULL
elements	NULL
became	NULL
important	NULL
in	NULL
stimulated	NULL
monocytes/	NULL
macrophages	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
very	NULL
little	NULL
has	NULL
been	NULL
done	NULL
to	NULL
address	NULL
the	NULL
effects	NULL
of	NULL
NF-kB	NULL
and	NULL
Spl	NULL
binding	NULL
site	NULL
mutations	NULL
on	NULL
the	NULL
replication	NULL
of	NULL
the	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
SIV	NULL
)	NULL
SIVmac	NULL
and	NULL
HIV-2	NULL
in	NULL
T-cell	NULL
lines	NULL
,	NULL
primary	NULL
lymphocytes	NULL
,	NULL
and	NULL
primary	NULL
macrophages	NULL
.	NULL

Bellas	NULL
et	NULL
al	NULL
.	NULL

(	NULL
2	NULL
)	NULL
studied	NULL
an	NULL
NF-kB	NULL
binding	NULL
site	NULL
mutant	NULL
of	NULL
SIVmac	NULL
and	NULL
found	NULL
a	NULL
much	NULL
greater	NULL
effect	NULL
on	NULL
replication	NULL
in	NULL
primary	NULL
macrophages	NULL
than	NULL
in	NULL
cell	NULL
lines	NULL
or	NULL
primary	NULL
lymphocytes	NULL
.	NULL

The	NULL
transcriptional	NULL
control	NULL
region	NULL
of	NULL
the	NULL
pathogenic	NULL
SIV	NULL
clone	NULL
SIVmac239	NULL
contains	NULL
a	NULL
TATA	NULL
box	NULL
,	NULL
four	NULL
putative	NULL
Spl	NULL
binding	NULL
sites	NULL
,	NULL
and	NULL
only	NULL
one	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
(	NULL
36	NULL
)	NULL
.	NULL

While	NULL
similar	NULL
to	NULL
the	NULL
TCE	NULL
of	NULL
HIV-1	NULL
(	NULL
37	NULL
,	NULL
42	NULL
)	NULL
,	NULL
the	NULL
SIVmac	NULL
structure	NULL
is	NULL
closer	NULL
to	NULL
that	NULL
of	NULL
HIV-2	NULL
(	NULL
13	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Previous	NULL
transfection	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
HIV-2	NULL
and	NULL
SIVmac	NULL
contain	NULL
additional	NULL
enhancer	NULL
elements	NULL
that	NULL
are	NULL
not	NULL
found	NULL
in	NULL
HIV-1	NULL
,	NULL
that	NULL
are	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
NF-kB	NULL
binding	NULL
site	NULL
,	NULL
and	NULL
that	NULL
are	NULL
responsive	NULL
to	NULL
T-cell	NULL
receptor	NULL
and	NULL
monocyte	NULL
stimulation	NULL
(	NULL
5	NULL
,	NULL
25	NULL
,	NULL
26	NULL
,	NULL
37	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
describe	NULL
the	NULL
characteristics	NULL
of	NULL
variant	NULL
SIVmac239	NULL
strains	NULL
with	NULL
extensively	NULL
mutagenized	NULL
TCEs	NULL
.	NULL

Their	NULL
growth	NULL
capacities	NULL
exhibited	NULL
in	NULL
primary	NULL
macaque	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
,	NULL
primary	NULL
macrophages	NULL
,	NULL
and	NULL
Vou	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
SIV	NULL
TRANSCRIPTION	NULL
AND	NULL
REPLICATION	NULL
WITHOUT	NULL
NF-	NULL
«	NULL
B	NULL
OR	NULL
Spi	NULL
3119	NULL
MUTATION	NULL
SEQUENCE	NULL
VIRUS	NULL
Stop-codon	NULL
for	NULL
nef	NULL
gene	NULL
|	NULL
NF-kB	NULL
Spl	NULL
Spl	NULL
Spl	NULL
Spl	NULL
TATA-box	NULL
9866	NULL
19880	NULL
9890	NULL
|	NULL
2900	NULL
|_	NULL
9910	NULL
|_	NULL
92920	NULL
|	NULL
9930	NULL
9940	NULL
9950	NULL
|	NULL
9962	NULL
None	NULL
$	NULL
IVmac239	NULL
NF-KB	NULL
deletion	NULL
|	NULL
eens	NULL
eer	NULL
%	NULL
%	NULL
%	NULL
es	NULL
ess	NULL
cers	NULL
r	NULL
rere	NULL
rk	NULL
kk	NULL
k	NULL
%	NULL
%	NULL
eee	NULL
erea	NULL
sere	NULL
eek	NULL
e	NULL
reer	NULL
nees	NULL
rere	NULL
e	NULL
SIVANFKB	NULL
Spl	NULL
deletion	NULL
|	NULL
.k	NULL
666k	NULL
k=	NULL
m=	NULL
...	NULL
.	NULL

eer	NULL
rre	NULL
ea	NULL
eee	NULL
ne	NULL
ees	NULL
een	NULL
ene	NULL
ees	NULL
SIVASp1234	NULL
AGACAGCAGGGACTTTCCACAA	NULL
I	NULL
oc	NULL
o	NULL
ee	NULL
SIV/2xNFKB	NULL
Point	NULL
mutation	NULL
|	NULL
...	NULL
...	NULL
...	NULL
.	NULL

CIC	NULL
.	NULL

...	NULL
..	NULL
kee	NULL
k	NULL
66k	NULL
keene	NULL
e	NULL
ened	NULL
ek	NULL
kn	NULL
ne	NULL
ee	NULL
d	NULL
n	NULL
n	NULL
nne	NULL
n	NULL
rae	NULL
ea	NULL
na	NULL
aa	NULL
e	NULL
ee	NULL
ee	NULL
en	NULL
ee	NULL
ee	NULL
ee	NULL
e	NULL
nee	NULL
ae	NULL
ee	NULL
ne	NULL
nene	NULL
ee	NULL
ee	NULL
ees	NULL
NFkB	NULL
of	NULL
NF-kB	NULL
NF-kB	NULL
and	NULL
Spl	NULL
-	NULL
aas	NULL
ere	NULL
e	NULL
eee	NULL
kee	NULL
eae	NULL
eek	NULL
e	NULL
ee	NULL
eee	NULL
nea	NULL
e	NULL
e	NULL
6	NULL
SIVANFKBASp1234	NULL
complete	NULL
deletion	NULL
NF-kB	NULL
and	NULL
18t	NULL
|	NULL
eke	NULL
6636	NULL
seer	NULL
errs	NULL
er	NULL
ek	NULL
6	NULL
keene	NULL
rs	NULL
errr	NULL
eae	NULL
en	NULL
enne	NULL
enna	NULL
a	NULL
e	NULL
nes	NULL
SIVANFkBASp1	NULL
Spl	NULL
deletion	NULL
Substitution	NULL
Of	NULL
|	NULL
eke	NULL
TCAAGCACCTGACTATCTGCAL	NULL
.	NULL

.	NULL

...	NULL
...	NULL
...	NULL
...	NULL
.k	NULL
...	NULL
es	NULL
eka	NULL
k	NULL
keke	NULL
ee	NULL
ne	NULL
ee	NULL
eee	NULL
neenee	NULL
eee	NULL
enn	NULL
SIVsubstSp12	NULL
1st	NULL
and	NULL
2nd	NULL
Spl	NULL
Substitution	NULL
Of	NULL
|_	NULL
6k	NULL
keer	NULL
seks	NULL
err	NULL
ee	NULL
ee	NULL
ekke	NULL
eee	NULL
eee	NULL
ek	NULL
eee	NULL
+	NULL
$	NULL
IVsubst	NULL
$	NULL
p23	NULL
2nd	NULL
and	NULL
3rd	NULL
Spl	NULL
Subst1tUut1On	NULL
Of	NULL
|	NULL
re	NULL
kee	NULL
eke	NULL
ee	NULL
eee	NULL
eee	NULL
eee	NULL
ee	NULL
eee	NULL
kkk	NULL
6.0	NULL
.	NULL

$	NULL
IVsubstSp34	NULL
3rd	NULL
and	NULL
4th	NULL
Spl	NULL
Substitution	NULL
|_	NULL
...	NULL
.	NULL

kk	NULL
666k	NULL
seen	NULL
e	NULL
SIVsubstSp1234	NULL
of	NULL
all	NULL
Spl	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Mutations	NULL
in	NULL
SIVmac239	NULL
transcriptional	NULL
control	NULL
elements	NULL
.	NULL

The	NULL
nature	NULL
of	NULL
the	NULL
introduced	NULL
mutations	NULL
,	NULL
their	NULL
sequence	NULL
,	NULL
and	NULL
the	NULL
designations	NULL
of	NULL
respective	NULL
mutant	NULL
viruses	NULL
are	NULL
shown	NULL
.	NULL

Proviral	NULL
SIVmac239	NULL
genome	NULL
sequences	NULL
can	NULL
be	NULL
found	NULL
in	NULL
an	NULL
article	NULL
by	NULL
Regier	NULL
and	NULL
Desrosiers	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Dots	NULL
indicate	NULL
identities	NULL
in	NULL
sequence	NULL
,	NULL
and	NULL
dashes	NULL
indicate	NULL
deletions	NULL
.	NULL

The	NULL
stop	NULL
codon	NULL
for	NULL
the	NULL
nef	NULL
gene	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
,	NULL
and	NULL
the	NULL
TATA	NULL
box	NULL
are	NULL
underlined	NULL
.	NULL

Mutant	NULL
SIV/2xNFKB	NULL
contains	NULL
an	NULL
insertion	NULL
of	NULL
the	NULL
sequence	NULL
shown	NULL
between	NULL
nucleotides	NULL
9889	NULL
and	NULL
9890	NULL
,	NULL
creating	NULL
a	NULL
duplication	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
.	NULL

CEMx174	NULL
cells	NULL
,	NULL
taken	NULL
together	NULL
with	NULL
additional	NULL
data	NULL
on	NULL
LTR-driven	NULL
transcription	NULL
,	NULL
show	NULL
that	NULL
even	NULL
the	NULL
total	NULL
loss	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
sites	NULL
in	NULL
SIVmac	NULL
may	NULL
be	NULL
partially	NULL
or	NULL
completely	NULL
compensated	NULL
for	NULL
by	NULL
unique	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
SIVmac	NULL
enhancer/promoter	NULL
region	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Construction	NULL
of	NULL
mutated	NULL
viruses	NULL
.	NULL

Ten	NULL
mutants	NULL
of	NULL
SIVmac239/nef-open	NULL
bearing	NULL
changes	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Spl	NULL
binding	NULL
sites	NULL
were	NULL
created	NULL
by	NULL
means	NULL
of	NULL
site-specific	NULL
mutagenesis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
mutations	NULL
were	NULL
introduced	NULL
into	NULL
both	NULL
proviral	NULL
LTRs	NULL
.	NULL

The	NULL
wild-type	NULL
SIVmac239	NULL
was	NULL
previously	NULL
cloned	NULL
in	NULL
two	NULL
parts	NULL
and	NULL
is	NULL
carried	NULL
on	NULL
plasmids	NULL
p239SpSpS5	NULL
'	NULL
(	NULL
5	NULL
'	NULL
clone	NULL
)	NULL
and	NULL
p239SpE3	NULL
'	NULL
(	NULL
3	NULL
'	NULL
clone	NULL
)	NULL
,	NULL
which	NULL
contain	NULL
the	NULL
left	NULL
and	NULL
right	NULL
halves	NULL
of	NULL
the	NULL
genome	NULL
,	NULL
respectively	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
this	NULL
work	NULL
,	NULL
we	NULL
have	NULL
used	NULL
a	NULL
modified	NULL
3	NULL
'	NULL
clone	NULL
of	NULL
SIVmac239	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Z	NULL
.	NULL

Du	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
)	NULL
,	NULL
in	NULL
which	NULL
an	NULL
additional	NULL
EcoRI	NULL
site	NULL
was	NULL
introduced	NULL
just	NULL
after	NULL
the	NULL
viral	NULL
sequence	NULL
and	NULL
from	NULL
which	NULL
the	NULL
cellular	NULL
DNA	NULL
sequences	NULL
were	NULL
eliminated	NULL
.	NULL

The	NULL
resulting	NULL
3,834-bp	NULL
SphI-EcoRI	NULL
viral	NULL
DNA	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
plasmid	NULL
pSp72	NULL
.	NULL

The	NULL
use	NULL
of	NULL
this	NULL
construct	NULL
significantly	NULL
simplified	NULL
subcloning	NULL
and	NULL
recloning	NULL
procedures	NULL
.	NULL

The	NULL
viral	NULL
sequence	NULL
in	NULL
this	NULL
3	NULL
'	NULL
clone	NULL
is	NULL
identical	NULL
to	NULL
that	NULL
in	NULL
the	NULL
3	NULL
'	NULL
clone	NULL
used	NULL
previously	NULL
(	NULL
36	NULL
)	NULL
,	NULL
except	NULL
that	NULL
the	NULL
flanking	NULL
cellular	NULL
sequences	NULL
have	NULL
been	NULL
removed	NULL
and	NULL
the	NULL
stop	NULL
codon	NULL
in	NULL
nef	NULL
has	NULL
been	NULL
repaired	NULL
to	NULL
Glu	NULL
.	NULL

The	NULL
854-bp	NULL
Secl-EcoRI	NULL
fragment	NULL
of	NULL
the	NULL
3	NULL
'	NULL
clone	NULL
was	NULL
then	NULL
subcloned	NULL
in	NULL
pSp72	NULL
and	NULL
used	NULL
for	NULL
the	NULL
introduction	NULL
of	NULL
site-specific	NULL
mutations	NULL
.	NULL

We	NULL
have	NULL
employed	NULL
PCR-directed	NULL
mutagenesis	NULL
(	NULL
17	NULL
)	NULL
with	NULL
one	NULL
or	NULL
two	NULL
mutagenic	NULL
primers	NULL
and	NULL
two	NULL
terminal	NULL
primers	NULL
in	NULL
each	NULL
reaction	NULL
mixture	NULL
.	NULL

Terminal	NULL
primers	NULL
spanned	NULL
Bsu	NULL
361	NULL
and	NULL
PMI	NULL
sites	NULL
,	NULL
which	NULL
are	NULL
unique	NULL
in	NULL
the	NULL
reconstructed	NULL
3	NULL
'	NULL
subclone	NULL
.	NULL

The	NULL
resulting	NULL
528-bp	NULL
fragment	NULL
was	NULL
digested	NULL
with	NULL
those	NULL
enzymes	NULL
and	NULL
inserted	NULL
into	NULL
the	NULL
Secl-EcoRI	NULL
subclone	NULL
.	NULL

In	NULL
some	NULL
instances	NULL
,	NULL
the	NULL
mutation-containing	NULL
PCR	NULL
product	NULL
was	NULL
initially	NULL
cloned	NULL
into	NULL
blunt-end	NULL
cloning	NULL
vector	NULL
(	NULL
PCRII	NULL
;	NULL
Invitrogen	NULL
Corp.	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
or	NULL
pUC18/SmaI	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
,	NULL
and	NULL
then	NULL
,	NULL
upon	NULL
sequence	NULL
verification	NULL
,	NULL
recloned	NULL
back	NULL
into	NULL
the	NULL
Secl-EcoRI	NULL
subclone	NULL
;	NULL
the	NULL
SpAI-Sacl	NULL
fragment	NULL
of	NULL
proviral	NULL
DNA	NULL
was	NULL
then	NULL
cloned	NULL
into	NULL
this	NULL
mutated	NULL
subclone	NULL
,	NULL
thus	NULL
creating	NULL
a	NULL
full	NULL
3	NULL
'	NULL
clone	NULL
of	NULL
SIVmac239	NULL
.	NULL

The	NULL
mutated	NULL
clones	NULL
were	NULL
multiply	NULL
sequenced	NULL
through	NULL
the	NULL
TCE	NULL
region	NULL
and	NULL
all	NULL
restriction	NULL
sites	NULL
used	NULL
in	NULL
mutagenesis	NULL
.	NULL

The	NULL
introduction	NULL
of	NULL
TCE	NULL
mutations	NULL
into	NULL
the	NULL
5	NULL
'	NULL
clone	NULL
was	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
SphI-Sacl	NULL
fragment	NULL
of	NULL
the	NULL
SIVmac	NULL
macrophage-competent	NULL
strain	NULL
MER	NULL
was	NULL
inserted	NULL
into	NULL
the	NULL
mutated	NULL
subclones	NULL
for	NULL
the	NULL
creation	NULL
of	NULL
TCE	NULL
mutants	NULL
of	NULL
SIVmacMER	NULL
.	NULL

This	NULL
strain	NULL
differs	NULL
from	NULL
SIVmac239	NULL
only	NULL
by	NULL
three	NULL
amino	NULL
acid	NULL
changes	NULL
in	NULL
the	NULL
env	NULL
gene	NULL
,	NULL
which	NULL
are	NULL
located	NULL
in	NULL
the	NULL
3	NULL
'	NULL
part	NULL
of	NULL
the	NULL
virus	NULL
genome	NULL
between	NULL
the	NULL
SphI	NULL
and	NULL
SacI	NULL
sites	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Molecular	NULL
cloning	NULL
.	NULL

All	NULL
routine	NULL
cloning	NULL
procedures	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Epicurian	NULL
Coli	NULL
XL1-Blue	NULL
MRF	NULL
'	NULL
Supercompetent	NULL
Cells	NULL
(	NULL
Stratagene	NULL
Cloning	NULL
Systems	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
were	NULL
used	NULL
for	NULL
the	NULL
transformation	NULL
and	NULL
plasmid	NULL
growth	NULL
.	NULL

Construction	NULL
of	NULL
mutated	NULL
secreted	NULL
engineered	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
SEAP	NULL
)	NULL
expression	NULL
plasmids	NULL
was	NULL
performed	NULL
with	NULL
wild-type	NULL
HIV	NULL
and	NULL
SIV	NULL
LTR-SEAP	NULL
plasmids	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
R.	NULL
Means	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
)	NULL
.	NULL

These	NULL
plasmids	NULL
contained	NULL
the	NULL
SEAP	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
viral	NULL
TCEs	NULL
(	NULL
nucleotides	NULL
9806	NULL
to	NULL
10093	NULL
for	NULL
SIV	NULL
and	NULL
9405	NULL
to	NULL
9611	NULL
for	NULL
HIV	NULL
)	NULL
,	NULL
which	NULL
included	NULL
all	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
,	NULL
the	NULL
TATA	NULL
box	NULL
,	NULL
and	NULL
the	NULL
full	NULL
transactivation-responsive	NULL
region	NULL
(	NULL
TAR	NULL
)	NULL
.	NULL

These	NULL
fragments	NULL
of	NULL
the	NULL
viral	NULL
LTRs	NULL
had	NULL
been	NULL
inserted	NULL
into	NULL
a	NULL
SEAP-containing	NULL
plasmid	NULL
between	NULL
unique	NULL
M/I	NULL
and	NULL
HindIII	NULL
sites	NULL
(	NULL
262	NULL
)	NULL
.	NULL

These	NULL
plasmids	NULL
were	NULL
used	NULL
for	NULL
PCR-directed	NULL
mutagenesis	NULL
for	NULL
the	NULL
creation	NULL
of	NULL
various	NULL
HIV	NULL
and	NULL
SIV	NULL
LTR-SEAP	NULL
constructs	NULL
.	NULL

Each	NULL
of	NULL
the	NULL
resulting	NULL
plasmids	NULL
was	NULL
sequenced	NULL
at	NULL
least	NULL
twice	NULL
through	NULL
the	NULL
viral	NULL
insert	NULL
.	NULL

PCR-amplified	NULL
viral	NULL
fragments	NULL
from	NULL
infected	NULL
culture	NULL
cell	NULL
lines	NULL
were	NULL
treated	NULL
with	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
cloned	NULL
into	NULL
pUC18/Smal-cut	NULL
vector	NULL
(	NULL
Pharmacia	NULL
)	NULL
according	NULL
to	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
.	NULL

Primers	NULL
.	NULL

All	NULL
nucleotide	NULL
primers	NULL
were	NULL
custom-made	NULL
by	NULL
Amitof	NULL
,	NULL
Inc.	NULL
(	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

or	NULL
GIBCO	NULL
BRL	NULL
(	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
.	NULL

The	NULL
terminal	NULL
primers	NULL
used	NULL
in	NULL
PCR	NULL
mutagenesis	NULL
were	NULL
5-GATTACACCTCAGGACCAGG-3	NULL
'	NULL
(	NULL
9548	NULL
to	NULL
9567	NULL
)	NULL
and	NULL
5-GCACCGGCCAAGTGCTGGTGA-3	NULL
'	NULL
(	NULL
10089	NULL
to	NULL
10069	NULL
)	NULL
.	NULL

Primers	NULL
5-GGG	NULL
ATTTATTACAGTGCAAGAAGA-3	NULL
'	NULL
(	NULL
6	NULL
to	NULL
29	NULL
)	NULL
and	NULL
5-GGCTAGGAGAGAT	NULL
GGGAACACACA-3	NULL
'	NULL
(	NULL
724	NULL
to	NULL
701	NULL
)	NULL
were	NULL
used	NULL
for	NULL
the	NULL
amplification	NULL
of	NULL
SIVmac	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
from	NULL
infected	NULL
cells	NULL
.	NULL

PCR	NULL
amplification	NULL
and	NULL
DNA	NULL
sequencing	NULL
.	NULL

PCR	NULL
amplification	NULL
and	NULL
DNA	NULL
sequencing	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
18	NULL
)	NULL
.	NULL

A	NULL
thermal	NULL
cycler	NULL
produced	NULL
by	NULL
MJ	NULL
Research	NULL
(	NULL
Watertown	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

was	NULL
used	NULL
for	NULL
PCR	NULL
amplification	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
analysis	NULL
.	NULL

Nucleotide	NULL
sequences	NULL
were	NULL
analyzed	NULL
and	NULL
aligned	NULL
by	NULL
using	NULL
MacVector	NULL
version	NULL
4.1.4.	NULL
software	NULL
(	NULL
International	NULL
Biotechnolo-gies	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
Haven	NULL
,	NULL
Conn.	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
SIVmac239	NULL
has	NULL
been	NULL
published	NULL
previously	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
HIV-1	NULL
NL4-3	NULL
was	NULL
taken	NULL
from	NULL
GenBank	NULL
(	NULL
accession	NULL
number	NULL
M19921	NULL
)	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Cells	NULL
.	NULL

Rhesus	NULL
monkey	NULL
PBMCs	NULL
,	NULL
CEMx174	NULL
,	NULL
and	NULL
COS-1	NULL
cells	NULL
were	NULL
maintained	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Alveolar	NULL
macrophages	NULL
were	NULL
obtained	NULL
from	NULL
bronchoal-veolar	NULL
lavage	NULL
specimens	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
,	NULL
from	NULL
healthy	NULL
,	NULL
mature	NULL
rhesus	NULL
macaques	NULL
that	NULL
were	NULL
serologically	NULL
negative	NULL
for	NULL
SIV	NULL
,	NULL
type	NULL
D	NULL
retrovirus	NULL
,	NULL
and	NULL
simian	NULL
foamy	NULL
virus	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Macrophages	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
GIBCO	NULL
Laboratories	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inac-tivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
2.5	NULL
%	NULL
human	NULL
type	NULL
AB	NULL
serum	NULL
(	NULL
GIBCO	NULL
)	NULL
,	NULL
penicillin	NULL
3120	NULL
ILYINSKII	NULL
AND	NULL
DESROSIERS	NULL
(	NULL
100	NULL
U/m	NULL
!	NULL
)	NULL

,	NULL
streptomycin	NULL
(	NULL
100	NULL
pg/m	NULL
!	NULL
)	NULL

,	NULL
and	NULL
amphotericin	NULL
B	NULL
(	NULL
0.25	NULL
to	NULL
0.5	NULL
pg/ml	NULL
)	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
in	NULL
24-	NULL
or	NULL
48-well	NULL
flat-bottom	NULL
plates	NULL
.	NULL

The	NULL
culture	NULL
medium	NULL
was	NULL
changed	NULL
twice	NULL
weekly	NULL
.	NULL

Preparation	NULL
of	NULL
virus	NULL
stocks	NULL
.	NULL

Pelleted	NULL
CEMx174	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
Sphl-digested	NULL
5'-	NULL
and	NULL
3'-SIVmac	NULL
plasmids	NULL
by	NULL
a	NULL
DEAE-dextran	NULL
procedure	NULL
(	NULL
31	NULL
)	NULL
.	NULL

For	NULL
stock	NULL
preparation	NULL
,	NULL
virus	NULL
was	NULL
harvested	NULL
at	NULL
or	NULL
near	NULL
the	NULL
peak	NULL
of	NULL
virus	NULL
produc-tion	NULL
,	NULL
filtered	NULL
,	NULL
and	NULL
stored	NULL
in	NULL
aliquots	NULL
at	NULL
-80°C	NULL
.	NULL

Stocks	NULL
were	NULL
assayed	NULL
for	NULL
the	NULL
concentration	NULL
of	NULL
SIV	NULL
p27	NULL
``	NULL
antigen	NULL
with	NULL
a	NULL
commercially	NULL
available	NULL
antigen	NULL
capture	NULL
kit	NULL
(	NULL
Coulter	NULL
Corp.	NULL
,	NULL
Hialeah	NULL
,	NULL
Fla.	NULL
)	NULL
.	NULL

Virus	NULL
replication	NULL
in	NULL
vitro	NULL
.	NULL

CEMx174	NULL
cells	NULL
split	NULL
1:3	NULL
the	NULL
previous	NULL
day	NULL
were	NULL
either	NULL
transfected	NULL
as	NULL
described	NULL
above	NULL
or	NULL
infected	NULL
with	NULL
an	NULL
aliquot	NULL
of	NULL
SIVmac	NULL
containing	NULL
2	NULL
ng	NULL
of	NULL
viral	NULL
p27	NULL
protein	NULL
.	NULL

Activated	NULL
PBMCs	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
SIVmac	NULL
upon	NULL
stimulation	NULL
with	NULL
phytohemagglutinin	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

as	NULL
described	NULL
previously	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Alveolar	NULL
macrophages	NULL
were	NULL
infected	NULL
1	NULL
day	NULL
after	NULL
their	NULL
isolation	NULL
with	NULL
SIVmac	NULL
containing	NULL
10	NULL
ng	NULL
of	NULL
p27	NULL
per	NULL
10°	NULL
cells	NULL
.	NULL

Cell	NULL
supernatants	NULL
were	NULL
sampled	NULL
,	NULL
clarified	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
SIV	NULL
p27	NULL
by	NULL
antigen	NULL
capture	NULL
.	NULL

Isolation	NULL
of	NULL
cellular	NULL
DNA	NULL
.	NULL

Infected	NULL
CEMx174	NULL
cells	NULL
were	NULL
pelleted	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
lysed	NULL
in	NULL
a	NULL
small	NULL
volume	NULL
(	NULL
50	NULL
to	NULL
100	NULL
pl	NULL
)	NULL
.	NULL

DNA	NULL
was	NULL
isolated	NULL
in	NULL
a	NULL
single	NULL
microcen-trifuge	NULL
tube	NULL
for	NULL
each	NULL
sample	NULL
with	NULL
the	NULL
HRI	NULL
AmpPrep	NULL
kit	NULL
(	NULL
HRI	NULL
Research	NULL
,	NULL
Inc.	NULL
,	NULL
Concord	NULL
,	NULL
Calif.	NULL
)	NULL
and	NULL
subjected	NULL
to	NULL
the	NULL
PCR	NULL
amplification	NULL
technique	NULL
described	NULL
above	NULL
.	NULL

SEAP	NULL
assay	NULL
.	NULL

COS-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
various	NULL
HIV	NULL
or	NULL
SIV	NULL
LTR-SEAP	NULL
plasmids	NULL
(	NULL
1	NULL
pg	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
DEAE-dextran	NULL
(	NULL
7	NULL
)	NULL
1	NULL
day	NULL
after	NULL
being	NULL
split	NULL
.	NULL

SEAP	NULL
in	NULL
the	NULL
culture	NULL
supernatant	NULL
was	NULL
detected	NULL
16	NULL
to	NULL
18	NULL
h	NULL
later	NULL
with	NULL
the	NULL
Phospha-Light	NULL
chemiluminescent	NULL
reporter	NULL
gene	NULL
assay	NULL
system	NULL
(	NULL
Tropix	NULL
,	NULL
Inc.	NULL
,	NULL
Bed-ford	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
.	NULL

Each	NULL
assay	NULL
was	NULL
done	NULL
in	NULL
triplicate	NULL
.	NULL

Each	NULL
experiment	NULL
was	NULL
performed	NULL
three	NULL
to	NULL
six	NULL
times	NULL
separately	NULL
.	NULL

RESULTS	NULL
Replication	NULL
of	NULL
SIVmac239	NULL
TCE	NULL
mutants	NULL
in	NULL
vitro	NULL
.	NULL

TCE	NULL
mutations	NULL
were	NULL
placed	NULL
into	NULL
both	NULL
LTRs	NULL
to	NULL
prevent	NULL
generation	NULL
of	NULL
parental	NULL
sequences	NULL
by	NULL
recombinational	NULL
or	NULL
replicative	NULL
events	NULL
.	NULL

All	NULL
SIVmac239	NULL
TCE	NULL
mutants	NULL
replicated	NULL
in	NULL
CEMx174	NULL
cells	NULL
after	NULL
transfection	NULL
of	NULL
cloned	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

While	NULL
most	NULL
mutants	NULL
consistently	NULL
replicated	NULL
with	NULL
kinetics	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
appearance	NULL
of	NULL
several	NULL
mutants	NULL
was	NULL
delayed	NULL
.	NULL

The	NULL
replication	NULL
of	NULL
mutant	NULL
viruses	NULL
ANFkBASpl	NULL
and	NULL
substSp34	NULL
was	NULL
slightly	NULL
delayed	NULL
,	NULL
and	NULL
the	NULL
replication	NULL
of	NULL
ANFkBASp1234	NULL
and	NULL
substSp1234	NULL
was	NULL
substantially	NULL
delayed	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
latter	NULL
two	NULL
viruses	NULL
are	NULL
the	NULL
most	NULL
severely	NULL
altered	NULL
of	NULL
all	NULL
the	NULL
mutants	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Virus	NULL
stocks	NULL
prepared	NULL
from	NULL
transfection	NULL
were	NULL
used	NULL
to	NULL
infect	NULL
CEMx174	NULL
cells	NULL
with	NULL
amounts	NULL
normalized	NULL
to	NULL
contain	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
CA	NULL
antigen	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
replication	NULL
after	NULL
infection	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
after	NULL
transfection	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

The	NULL
greatest	NULL
delays	NULL
in	NULL
replication	NULL
were	NULL
observed	NULL
with	NULL
ANFkBASp1234	NULL
,	NULL
ANFkBASp1l	NULL
,	NULL
and	NULL
substSp1234	NULL
.	NULL

All	NULL
mutant	NULL
viruses	NULL
ultimately	NULL
reached	NULL
similar	NULL
levels	NULL
of	NULL
virus	NULL
production	NULL
in	NULL
CEMx174	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

The	NULL
replication	NULL
of	NULL
mutant	NULL
viruses	NULL
was	NULL
also	NULL
examined	NULL
with	NULL
phytohemagglutinin-stimulated	NULL
PBMCs	NULL
from	NULL
rhesus	NULL
monkeys	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
interleukin	NULL
2	NULL
.	NULL

Normalized	NULL
amounts	NULL
of	NULL
virus	NULL
containing	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
were	NULL
again	NULL
used	NULL
for	NULL
infection	NULL
.	NULL

The	NULL
replication	NULL
of	NULL
mutant	NULL
viruses	NULL
in	NULL
rhesus	NULL
monkey	NULL
PBMCs	NULL
was	NULL
not	NULL
significantly	NULL
delayed	NULL
in	NULL
most	NULL
cases	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
severely	NULL
altered	NULL
mutant	NULL
ANFkBASp1234	NULL
was	NULL
not	NULL
delayed	NULL
in	NULL
four	NULL
of	NULL
four	NULL
ex-periments	NULL
,	NULL
and	NULL
viruses	NULL
ANFkBASp1l	NULL
and	NULL
substSp1234	NULL
exhibited	NULL
wild-type	NULL
kinetics	NULL
in	NULL
two	NULL
of	NULL
four	NULL
experiments	NULL
.	NULL

Representative	NULL
results	NULL
of	NULL
the	NULL
replication	NULL
of	NULL
SIVmac239	NULL
TCE	NULL
mutants	NULL
in	NULL
rhesus	NULL
PBMCs	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

A	NULL
summary	NULL
of	NULL
the	NULL
results	NULL
of	NULL
all	NULL
experiments	NULL
is	NULL
presented	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Sequence	NULL
of	NULL
the	NULL
TCE	NULL
region	NULL
in	NULL
SIVmac239-infected	NULL
cells	NULL
.	NULL

Total	NULL
cellular	NULL
DNA	NULL
from	NULL
SIV	NULL
-infected	NULL
CEMx174	NULL
cell	NULL
cultures	NULL
was	NULL
used	NULL
for	NULL
PCR	NULL
amplification	NULL
of	NULL
the	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Multiple	NULL
clones	NULL
were	NULL
derived	NULL
and	NULL
sequenced	NULL
through	NULL
the	NULL
TCE	NULL
of	NULL
each	NULL
mutant	NULL
.	NULL

The	NULL
clones	NULL
derived	NULL
from	NULL
ANFkBASp1234	NULL
(	NULL
six	NULL
clones	NULL
)	NULL
and	NULL
substSp1234	NULL
(	NULL
four	NULL
clones	NULL
)	NULL
were	NULL
sequenced	NULL
through	NULL
all	NULL
of	NULL
the	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
.	NULL

No	NULL
reversions	NULL
in	NULL
the	NULL
TCE	NULL
were	NULL
detected	NULL
,	NULL
and	NULL
except	NULL
for	NULL
an	NULL
occasional	NULL
sporadic	NULL
mutation	NULL
in	NULL
a	NULL
single	NULL
clone	NULL
,	NULL
no	NULL
other	NULL
mutations	NULL
that	NULL
could	NULL
possibly	NULL
explain	NULL
the	NULL
J.	NULL
ViroL	NULL
.	NULL

1200	NULL
A	NULL
10007	NULL
800	NULL
600	NULL
-	NULL
]	NULL
p27	NULL
,	NULL
ng/ml	NULL
400	NULL
-	NULL
]	NULL
200	NULL
3	NULL
60	NULL
9	NULL
11	NULL
18	NULL
17	NULL
20	NULL
24	NULL
28	NULL
33	NULL
Days	NULL
after	NULL
transfection	NULL
p27	NULL
,	NULL
ng/ml	NULL
L	NULL
0.001	NULL
s	NULL
1	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
1	NULL
3	NULL
4	NULL
6	NULL
8	NULL
9	NULL
11	NULL
15	NULL
16	NULL
18	NULL
20	NULL
22	NULL
24	NULL
26	NULL
29	NULL
35	NULL
38	NULL
Days	NULL
after	NULL
transfection	NULL
100	NULL
ilan	NULL
a	NULL
caa	NULL
104	NULL
p27	NULL
,	NULL
ng/ml	NULL
017	NULL
0.01	NULL
1	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
T	NULL
1	NULL
3	NULL
5	NULL
7	NULL
10	NULL
14	NULL
17	NULL
21	NULL
26	NULL
Days	NULL
after	NULL
infection	NULL
,	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Replication	NULL
of	NULL
SIVmac239	NULL
TCE	NULL
mutants	NULL
in	NULL
CEMx174	NULL
cells	NULL
.	NULL

Results	NULL
of	NULL
transfection	NULL
with	NULL
SIVANFxB	NULL
,	NULL
SIVASp1234	NULL
,	NULL
SIV/2xNFxB	NULL
,	NULL
SIV	NULL
point	NULL
mutant	NULL
NFkB	NULL
,	NULL
SIVANFkBASp1234	NULL
,	NULL
and	NULL
SIVANFkBASp1	NULL
(	NULL
A	NULL
)	NULL
and	NULL
with	NULL
SIVsubstSp	NULL
mutants	NULL
(	NULL
B	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Virus	NULL
stocks	NULL
derived	NULL
from	NULL
the	NULL
transfections	NULL
described	NULL
above	NULL
were	NULL
used	NULL
for	NULL
infection	NULL
of	NULL
CEMx174	NULL
cells	NULL
.	NULL

Virus	NULL
containing	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
was	NULL
used	NULL
for	NULL
each	NULL
infection	NULL
.	NULL

Symbols	NULL
:	NULL
A	NULL
,	NULL
M	NULL
,	NULL
SIVANFxB	NULL
;	NULL
®	NULL
,	NULL
SIVASp1234	NULL
;	NULL
A	NULL
,	NULL
SIV/2x	NULL
NFxB	NULL
;	NULL
©	NULL
,	NULL
S	NULL
[	NULL
VsubstNFxB	NULL
;	NULL
C	NULL
,	NULL
SIVANFkBASp1234	NULL
;	NULL
O	NULL
,	NULL
SIVANFKkBASp1	NULL
;	NULL
A	NULL
,	NULL
SIV	NULL
mac239	NULL
;	NULL
B	NULL
,	NULL
M	NULL
,	NULL
SIVmac239	NULL
;	NULL
@	NULL
,	NULL
SIVsubstSp12	NULL
;	NULL
A	NULL
,	NULL
SIVsubstSp23	NULL
;	NULL
O	NULL
,	NULL
SIVsubst	NULL
Sp34	NULL
;	NULL
C	NULL
,	NULL
STVsubstSp1234	NULL
;	NULL
C	NULL
,	NULL
,	NULL
SIVANFKB	NULL
;	NULL
@	NULL
,	NULL
STIVASp1234	NULL
;	NULL
A	NULL
,	NULL
SIV/2xNFxB	NULL
;	NULL
©	NULL
,	NULL
STVsubstNF	NULL
«	NULL
B	NULL
;	NULL
C	NULL
,	NULL
SIVANFxBASp1234	NULL
;	NULL
O	NULL
,	NULL
SIVANFKkBASp1	NULL
;	NULL
A	NULL
,	NULL
SIVsubst	NULL
Sp12	NULL
;	NULL
©	NULL
,	NULL
SIVsubstSp23	NULL
;	NULL
EM	NULL
,	NULL
SIVsubstSp34	NULL
;	NULL
M	NULL
,	NULL
SIVsubstSp1234	NULL
;	NULL
©	NULL
,	NULL
SIVmac239	NULL
.	NULL

surprisingly	NULL
high	NULL
replicative	NULL
capacity	NULL
of	NULL
these	NULL
mutant	NULL
viruses	NULL
were	NULL
observed	NULL
.	NULL

Replication	NULL
of	NULL
SIVmacMER	NULL
TCE	NULL
mutants	NULL
in	NULL
vitro	NULL
.	NULL

We	NULL
also	NULL
wanted	NULL
to	NULL
test	NULL
the	NULL
replication	NULL
of	NULL
mutant	NULL
viruses	NULL
in	NULL
primary	NULL
macrophage	NULL
cultures	NULL
.	NULL

Since	NULL
SIVmac239	NULL
replicates	NULL
poorly	NULL
in	NULL
primary	NULL
cultures	NULL
of	NULL
rhesus	NULL
monkey	NULL
macrophages	NULL
(	NULL
9	NULL
,	NULL
28	NULL
)	NULL
,	NULL
we	NULL
transferred	NULL
the	NULL
TCE	NULL
mutations	NULL
into	NULL
a	NULL
different	NULL
genetic	NULL
back	NULL
voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
350-4	NULL
A	NULL
3	NULL
5	NULL
7	NULL
10	NULL
14	NULL
17	NULL
21	NULL
Days	NULL
after	NULL
infection	NULL
,	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
p27	NULL
,	NULL
ng/m	NULL
!	NULL

0.1	NULL
I	NULL
I	NULL
T	NULL
T	NULL
I	NULL
1	NULL
3	NULL
6	NULL
10	NULL
14	NULL
17	NULL
21	NULL
Days	NULL
after	NULL
infection	NULL
,	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Replication	NULL
of	NULL
SIVmac239	NULL
TCE	NULL
mutants	NULL
in	NULL
thesus	NULL
monkey	NULL
PBMCs	NULL
.	NULL

Virus	NULL
containing	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
was	NULL
used	NULL
for	NULL
each	NULL
infection	NULL
.	NULL

SIVmac239	NULL
was	NULL
used	NULL
in	NULL
parallel	NULL
.	NULL

The	NULL
results	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
with	NULL
PBMCs	NULL
from	NULL
two	NULL
different	NULL
thesus	NULL
monkeys	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

Symbols	NULL
:	NULL
MB	NULL
,	NULL
SIVANFxB	NULL
;	NULL
@	NULL
,	NULL
SIVASp1234	NULL
;	NULL
A	NULL
,	NULL
SIV/2xNFkB	NULL
;	NULL
®	NULL
,	NULL
C	NULL
,	NULL
SIVANFkBASp1234	NULL
;	NULL
O	NULL
,	NULL
SIVANFKkBASp1	NULL
;	NULL
A	NULL
,	NULL
SIVsubstSp12	NULL
;	NULL
©	NULL
,	NULL
SIVsubstSp23	NULL
;	NULL
E	NULL
,	NULL
SIVsubstSp34	NULL
;	NULL
@	NULL
,	NULL
SIV	NULL
substSp1234	NULL
;	NULL
©	NULL
,	NULL
SIVmac239	NULL
.	NULL

bone	NULL
.	NULL

SIV	NULL
macMER	NULL
contains	NULL
three	NULL
mutations	NULL
in	NULL
the	NULL
envelope	NULL
relative	NULL
to	NULL
SIVmac239	NULL
:	NULL
67V-M	NULL
,	NULL
176K-E	NULL
,	NULL
and	NULL
382G-R	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

These	NULL
mutations	NULL
confer	NULL
the	NULL
high	NULL
replicative	NULL
capacity	NULL
of	NULL
the	NULL
virus	NULL
for	NULL
primary	NULL
rhesus	NULL
monkey	NULL
macrophages	NULL
(	NULL
27	NULL
)	NULL
.	NULL

We	NULL
SIV	NULL
TRANSCRIPTION	NULL
AND	NULL
REPLICATION	NULL
WITHOUT	NULL
NF-	NULL
«	NULL
B	NULL
OR	NULL
Spi	NULL
3121	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
M	NULL
1	NULL
1636	NULL
1018	NULL
506/517	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

PCR	NULL
amplification	NULL
of	NULL
proviral	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
from	NULL
the	NULL
DNA	NULL
of	NULL
infected	NULL
CEMx174	NULL
cells	NULL
.	NULL

DNAs	NULL
from	NULL
the	NULL
cultures	NULL
infected	NULL
with	NULL
SIVANFkB	NULL
,	NULL
SIVASp1234	NULL
,	NULL
SIV/2xNFkB	NULL
,	NULL
SIVsubstNFkB	NULL
,	NULL
SIVANFkBASp1234	NULL
,	NULL
and	NULL
SIVA	NULL
NFkBASp1	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
6	NULL
,	NULL
respectively	NULL
)	NULL
were	NULL
used	NULL
for	NULL
amplification	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
locations	NULL
of	NULL
molecular	NULL
size	NULL
markers	NULL
(	NULL
base	NULL
pairs	NULL
)	NULL
are	NULL
shown	NULL
to	NULL
the	NULL
left	NULL
.	NULL

thus	NULL
exchanged	NULL
the	NULL
TCE	NULL
mutations	NULL
into	NULL
the	NULL
background	NULL
of	NULL
SIVmacMER	NULL
and	NULL
analyzed	NULL
the	NULL
growth	NULL
properties	NULL
of	NULL
the	NULL
mutant	NULL
viruses	NULL
.	NULL

The	NULL
TCE	NULL
mutants	NULL
of	NULL
the	NULL
macrophage-competent	NULL
strain	NULL
SIV	NULL
macMER	NULL
replicated	NULL
in	NULL
CEMx174	NULL
cells	NULL
and	NULL
primary	NULL
rhesus	NULL
PBMC	NULL
cultures	NULL
similar	NULL
to	NULL
the	NULL
equivalent	NULL
mutants	NULL
of	NULL
SIVmac	NULL
239	NULL
.	NULL

SIVmacMER	NULL
viruses	NULL
ANF	NULL
«	NULL
BASp1234	NULL
,	NULL
substSp1234	NULL
,	NULL
substSp34	NULL
,	NULL
and	NULL
ANFKB	NULL
grew	NULL
with	NULL
a	NULL
delay	NULL
in	NULL
CEMx	NULL
174	NULL
cells	NULL
in	NULL
transfection	NULL
and	NULL
infection	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

As	NULL
with	NULL
SIVmac239	NULL
TCE	NULL
mutants	NULL
,	NULL
the	NULL
delay	NULL
in	NULL
replication	NULL
of	NULL
these	NULL
SIVmacMER	NULL
mutant	NULL
viruses	NULL
was	NULL
slightly	NULL
longer	NULL
after	NULL
transfection	NULL
than	NULL
after	NULL
infection	NULL
.	NULL

All	NULL
viruses	NULL
ultimately	NULL
reached	NULL
the	NULL
wild-type	NULL
level	NULL
of	NULL
production	NULL
in	NULL
CEMx174	NULL
cells	NULL
.	NULL

Only	NULL
SIVmacMERsubstSp1234	NULL
exhibited	NULL
a	NULL
slight	NULL
growth	NULL
delay	NULL
in	NULL
stimulated	NULL
rhesus	NULL
monkey	NULL
PBMCs	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
and	NULL
C	NULL
)	NULL
,	NULL
while	NULL
all	NULL
other	NULL
viruses	NULL
exhibited	NULL
wild-type	NULL
kinetics	NULL
and	NULL
levels	NULL
of	NULL
production	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
results	NULL
with	NULL
CEMx174	NULL
and	NULL
rhesus	NULL
macaque	NULL
PBMC	NULL
cultures	NULL
,	NULL
most	NULL
of	NULL
the	NULL
SIVmacMER	NULL
TCE	NULL
mutants	NULL
showed	NULL
both	NULL
delayed	NULL
and	NULL
suppressed	NULL
replication	NULL
in	NULL
primary	NULL
rhesus	NULL
macrophages	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
and	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

The	NULL
results	NULL
varied	NULL
slightly	NULL
in	NULL
macrophage	NULL
cultures	NULL
derived	NULL
from	NULL
different	NULL
animals	NULL
.	NULL

However	NULL
,	NULL
it	NULL
could	NULL
be	NULL
clearly	NULL
seen	NULL
that	NULL
only	NULL
2xNFxB	NULL
and	NULL
subst	NULL
NFkB	NULL
mutants	NULL
showed	NULL
a	NULL
wild-type	NULL
pattern	NULL
of	NULL
replication	NULL
TABLE	NULL
1	NULL
.	NULL

Replication	NULL
of	NULL
SIVmac239	NULL
TCE	NULL
mutants	NULL
in	NULL
vitro	NULL
Replication	NULL
capacity	NULL
``	NULL
Virus	NULL
CEMx174	NULL
cells	NULL
PBMCs	NULL
(	NULL
infection	NULL
)	NULL
Transfection	NULL
Infection	NULL
SIVANFkB	NULL
++++	NULL
(	NULL
1	NULL
)	NULL
++++	NULL
(	NULL
3	NULL
)	NULL
++++	NULL
(	NULL
4	NULL
)	NULL
(	NULL
slightly	NULL
delayed	NULL
once	NULL
)	NULL
``	NULL
SIVASp1234	NULL
++++	NULL
(	NULL
1	NULL
)	NULL
++++	NULL
(	NULL
3	NULL
)	NULL
(	NULL
slightly	NULL
delayed	NULL
once	NULL
)	NULL
++++	NULL
(	NULL
4	NULL
)	NULL
(	NULL
slightly	NULL
delayed	NULL
once	NULL
)	NULL
``	NULL
SIV/2xNFKB	NULL
+++++	NULL
(	NULL
2	NULL
)	NULL
At	NULL
least	NULL
++++	NULL
(	NULL
3	NULL
)	NULL
++++	NULL
(	NULL
4	NULL
)	NULL
SIVsubstNFxB	NULL
++++	NULL
(	NULL
1	NULL
)	NULL
++++	NULL
(	NULL
3	NULL
)	NULL
++++	NULL
(	NULL
4	NULL
)	NULL
(	NULL
delayed	NULL
once	NULL
)	NULL
``	NULL
SIVANFkBASp1234	NULL
Delayed	NULL
(	NULL
2	NULL
)	NULL
Delayed	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
4	NULL
)	NULL
SIVANFKBASpl	NULL
Delayed	NULL
once	NULL
(	NULL
2	NULL
)	NULL
Delayed	NULL
(	NULL
3	NULL
)	NULL
Delayed	NULL
twice	NULL
(	NULL
4	NULL
)	NULL
°	NULL
SIVsubstSp12	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
3	NULL
)	NULL
++++	NULL
(	NULL
4	NULL
)	NULL
SIVsubstSp23	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
3	NULL
)	NULL
++++	NULL
(	NULL
4	NULL
)	NULL
SIVsubstSp34	NULL
Delayed	NULL
(	NULL
1	NULL
)	NULL
Delayed	NULL
(	NULL
1	NULL
)	NULL
++++	NULL
(	NULL
4	NULL
)	NULL
(	NULL
slightly	NULL
delayed	NULL
twice	NULL
)	NULL
SIVsubstSp1234	NULL
Substantially	NULL
delayed	NULL
(	NULL
2	NULL
)	NULL
Delayed	NULL
(	NULL
2	NULL
)	NULL
Delayed	NULL
twice	NULL
(	NULL
4	NULL
)	NULL
``	NULL
++++	NULL
,	NULL
replication	NULL
reached	NULL
wild-type	NULL
level	NULL
(	NULL
no	NULL
less	NULL
than	NULL
50	NULL
%	NULL
)	NULL
with	NULL
no	NULL
or	NULL
an	NULL
unsubstantial	NULL
delay	NULL
compared	NULL
with	NULL
SIVmac239	NULL
;	NULL
+++++	NULL
,	NULL
replication	NULL
reached	NULL
the	NULL
peak	NULL
level	NULL
carlier	NULL
than	NULL
with	NULL
wild-type	NULL
SIVmac239	NULL
;	NULL
slightly	NULL
delayed	NULL
,	NULL
replication	NULL
reached	NULL
wild-type	NULL
levels	NULL
2	NULL
to	NULL
3	NULL
days	NULL
later	NULL
than	NULL
SIVmac239	NULL
;	NULL
delayed	NULL
,	NULL
replication	NULL
reached	NULL
wild-type	NULL
levels	NULL
4	NULL
to	NULL
7	NULL
days	NULL
later	NULL
than	NULL
SIVmac239	NULL
;	NULL
substantially	NULL
delayed	NULL
,	NULL
replication	NULL
reached	NULL
wild-type	NULL
levels	NULL
>	NULL
7	NULL
days	NULL
later	NULL
than	NULL
SIVmac239	NULL
.	NULL

The	NULL
number	NULL
of	NULL
experiments	NULL
for	NULL
cach	NULL
mutant	NULL
with	NULL
each	NULL
cell	NULL
type	NULL
is	NULL
shown	NULL
in	NULL
parentheses	NULL
.	NULL

*	NULL
In	NULL
this	NULL
case	NULL
,	NULL
replication	NULL
of	NULL
the	NULL
mutant	NULL
in	NULL
PBMCs	NULL
reached	NULL
30	NULL
%	NULL
of	NULL
the	NULL
wild-type	NULL
level	NULL
.	NULL

°	NULL
In	NULL
these	NULL
cases	NULL
,	NULL
replication	NULL
of	NULL
the	NULL
mutants	NULL
in	NULL
PBMCs	NULL
reached	NULL
10	NULL
and	NULL
30	NULL
%	NULL
of	NULL
the	NULL
wild-type	NULL
level	NULL
.	NULL

3122	NULL
ILYINSKII	NULL
AND	NULL
DESROSIERS	NULL
10000	NULL
<	NULL
A	NULL
1000	NULL
p27	NULL
,	NULL
ng/ml	NULL
T	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
1	NULL
3	NULL
6	NULL
7	NULL
10	NULL
13	NULL
14	NULL
17	NULL
20	NULL
21	NULL
24	NULL
29	NULL
Days	NULL
after	NULL
infection	NULL
,	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
p27	NULL
,	NULL
ng/ml	NULL
0.1	NULL
I	NULL
I	NULL
I	NULL
I	NULL
1	NULL
3	NULL
6	NULL
9	NULL
13	NULL
17	NULL
Days	NULL
after	NULL
infection	NULL
,	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
moo-EC	NULL
100	NULL
7	NULL
p27	NULL
,	NULL
ng/ml	NULL
35	NULL
1	NULL
0.1	NULL
I	NULL
I	NULL
T	NULL
I	NULL
1	NULL
4	NULL
7	NULL
11	NULL
16	NULL
20	NULL
Days	NULL
after	NULL
infection	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Replication	NULL
of	NULL
SIVmacMER	NULL
TCE	NULL
mutants	NULL
in	NULL
CEMx174	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
and	NULL
rhesus	NULL
monkey	NULL
PBMCs	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Virus	NULL
containing	NULL
2	NULL
ng	NULL
of	NULL
p27	NULL
was	NULL
used	NULL
for	NULL
each	NULL
infection	NULL
.	NULL

The	NULL
results	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
with	NULL
PBMCs	NULL
from	NULL
two	NULL
different	NULL
rhesus	NULL
monkeys	NULL
are	NULL
shown	NULL
.	NULL

Symbols	NULL
:	NULL
Ml	NULL
,	NULL
SIVmacMERANFB	NULL
;	NULL
@	NULL
,	NULL
SIVmac	NULL
MERASp1234	NULL
;	NULL
A	NULL
,	NULL
SIVmacMER/2xNFxB	NULL
;	NULL
®	NULL
,	NULL
SIVmacMERsubstNFxB	NULL
;	NULL
Q	NULL
,	NULL
SIV	NULL
macMERANFKkBASp1234	NULL
;	NULL
O	NULL
,	NULL
SIVmacMERANFBASp1	NULL
;	NULL
A	NULL
,	NULL
SIVmacMERsubst	NULL
Sp12	NULL
;	NULL
©	NULL
,	NULL
SIVmacMERsubstSp23	NULL
;	NULL
K	NULL
,	NULL
SIVmacMERsubstSp34	NULL
;	NULL
H	NULL
,	NULL
SIVmacMER	NULL
substSp1234	NULL
;	NULL
©	NULL
,	NULL
SIVmacMER	NULL
;	NULL
S	NULL
,	NULL
SIVmac239	NULL
.	NULL

in	NULL
all	NULL
experiments	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
SIVmacMER	NULL
to	NULL
replicate	NULL
in	NULL
primary	NULL
macrophages	NULL
was	NULL
impaired	NULL
to	NULL
various	NULL
degrees	NULL
by	NULL
all	NULL
other	NULL
TCE	NULL
mutations	NULL
.	NULL

Mutant	NULL
ANFkB	NULL
was	NULL
partially	NULL
af-fected	NULL
,	NULL
mutant	NULL
ANFkBASp1l	NULL
was	NULL
even	NULL
more	NULL
suppressed	NULL
,	NULL
mutants	NULL
and	NULL
substSp12	NULL
grew	NULL
to	NULL
a	NULL
significant	NULL
level	NULL
in	NULL
only	NULL
one	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
,	NULL
and	NULL
the	NULL
other	NULL
mutants	NULL
(	NULL
ASp1234	NULL
,	NULL
substSp23	NULL
,	NULL
substSp34	NULL
,	NULL
and	NULL
substSp1234	NULL
)	NULL
never	NULL
exhibited	NULL
substantial	NULL
growth	NULL
in	NULL
primary	NULL
rhesus	NULL
macrophages	NULL
.	NULL

A	NULL
summary	NULL
of	NULL
the	NULL
replicative	NULL
capacities	NULL
of	NULL
SIVmacMER	NULL
TCE	NULL
mutants	NULL
in	NULL
vitro	NULL
is	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

Different	NULL
transcriptional	NULL
activities	NULL
of	NULL
SIV	NULL
and	NULL
HIV	NULL
LTR	NULL
sequences	NULL
with	NULL
mutations	NULL
in	NULL
the	NULL
TCE	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
explain	NULL
the	NULL
significant	NULL
replicative	NULL
capacities	NULL
of	NULL
SIVmac	NULL
strains	NULL
with	NULL
severely	NULL
altered	NULL
TCEs	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
number	NULL
of	NULL
reporter	NULL
plasmids	NULL
in	NULL
which	NULL
the	NULL
gene	NULL
for	NULL
SEAP	NULL
was	NULL
expressed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
HIV	NULL
or	NULL
SIV	NULL
LTR	NULL
sequences	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

The	NULL
elimination	NULL
of	NULL
all	NULL
NF-kB	NULL
and	NULL
Spl	NULL
binding	NULL
sites	NULL
from	NULL
the	NULL
HIV	NULL
LTR	NULL
reduced	NULL
SEAP	NULL
activity	NULL
in	NULL
transfected	NULL
COS-1	NULL
cells	NULL
to	NULL
background	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

This	NULL
represents	NULL
a	NULL
reduction	NULL
of	NULL
greater	NULL
than	NULL
200-fold	NULL
.	NULL

Coexpression	NULL
of	NULL
Tat	NULL
was	NULL
able	NULL
to	NULL
increase	NULL
SEAP	NULL
expression	NULL
driven	NULL
by	NULL
the	NULL
nonmutated	NULL
HIV	NULL
LTR	NULL
approximately	NULL
14-fold	NULL
,	NULL
but	NULL
it	NULL
was	NULL
not	NULL
able	NULL
to	NULL
increase	NULL
expression	NULL
from	NULL
the	NULL
NF-kB-	NULL
and	NULL
Sp1-deleted	NULL
form	NULL
over	NULL
background	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
and	NULL
E	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
deletion	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
elements	NULL
from	NULL
the	NULL
SIV	NULL
LTR	NULL
did	NULL
not	NULL
abolish	NULL
SEAP	NULL
expression	NULL
from	NULL
the	NULL
corresponding	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
SIV-SEAP	NULL
plasmid	NULL
missing	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Spl	NULL
binding	NULL
sites	NULL
retained	NULL
approximately	NULL
10	NULL
%	NULL
of	NULL
its	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
.	NULL

Sequences	NULL
upstream	NULL
of	NULL
the	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
SIV	NULL
LTR	NULL
were	NULL
principally	NULL
responsible	NULL
for	NULL
this	NULL
residual	NULL
activity	NULL
,	NULL
since	NULL
their	NULL
removal	NULL
reduced	NULL
the	NULL
residual	NULL
expression	NULL
from	NULL
10	NULL
%	NULL
to	NULL
2	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
.	NULL

Enhanced	NULL
transcription	NULL
caused	NULL
by	NULL
these	NULL
upstream	NULL
sequences	NULL
was	NULL
also	NULL
responsive	NULL
to	NULL
Tat	NULL
transactivation	NULL
(	NULL
Fig	NULL
.	NULL

8D	NULL
and	NULL
E	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
these	NULL
upstream	NULL
enhancer	NULL
elements	NULL
,	NULL
the	NULL
SIV	NULL
LTR	NULL
appeared	NULL
to	NULL
contain	NULL
a	NULL
slightly	NULL
more	NULL
efficient	NULL
TATA	NULL
box	NULL
than	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
to	NULL
D	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
HIV	NULL
LTR	NULL
reporter	NULL
plasmid	NULL
used	NULL
for	NULL
the	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
contained	NULL
only	NULL
20	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
NF-kB	NULL
and	NULL
Spl	NULL
140	NULL
-A	NULL
120	NULL
100	NULL
so	NULL
p27	NULL
,	NULL
ng/ml	NULL
60	NULL
40	NULL
p27	NULL
,	NULL
ng/ml	NULL
3	NULL
6	NULL
9	NULL
13	NULL
17	NULL
21	NULL
24	NULL
27	NULL
31	NULL
Days	NULL
after	NULL
infection	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Replication	NULL
of	NULL
STVmacMER	NULL
TCE	NULL
mutants	NULL
in	NULL
primary	NULL
rhesus	NULL
monkey	NULL
macrophages	NULL
.	NULL

Virus	NULL
containing	NULL
10	NULL
ng	NULL
of	NULL
p27	NULL
was	NULL
used	NULL
to	NULL
infect	NULL
10°	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
of	NULL
two	NULL
separate	NULL
experiments	NULL
with	NULL
macrophages	NULL
from	NULL
two	NULL
different	NULL
rhesus	NULL
monkeys	NULL
are	NULL
shown	NULL
.	NULL

Symbols	NULL
are	NULL
the	NULL
same	NULL
as	NULL
those	NULL
in	NULL
Fig	NULL
.	NULL

5.	NULL
voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
TABLE	NULL
2	NULL
.	NULL

Replication	NULL
of	NULL
SIVmacMER	NULL
TCE	NULL
mutants	NULL
in	NULL
vitro	NULL
Replication	NULL
capacity	NULL
``	NULL
Virus	NULL
Primary	NULL
CEMx174	NULL
PBMCs	NULL
macro-cells	NULL
phages	NULL
SIVmacMERANFKB	NULL
Delayed	NULL
once	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
+++	NULL
(	NULL
3	NULL
)	NULL
SIVmacMERASp1234	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
+	NULL
(	NULL
3	NULL
)	NULL
SIVmacMER/2xNFxB	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
3	NULL
)	NULL
SIVmacMERsubstNFKB	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
3	NULL
)	NULL
SIVmacMERANFkBASp1234	NULL
Delayed	NULL
(	NULL
3	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++	NULL
(	NULL
3	NULL
)	NULL
*	NULL
SIVmacMERANFkBASpl	NULL
Delayed	NULL
(	NULL
3	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++	NULL
(	NULL
3	NULL
)	NULL
SIVmacMERsubstSp12	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++	NULL
(	NULL
3	NULL
)	NULL
SIVmacMERsubst	NULL
$	NULL
p23	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
+	NULL
(	NULL
3	NULL
)	NULL
SIVmacMERsubstSp34	NULL
Delayed	NULL
(	NULL
2	NULL
)	NULL
++++	NULL
(	NULL
2	NULL
)	NULL
+	NULL
(	NULL
3	NULL
)	NULL
SIVmacMERsubstSp1234	NULL
Delayed	NULL
in	NULL
3	NULL
of	NULL
_	NULL
Slightly	NULL
de-	NULL
+	NULL
(	NULL
3	NULL
)	NULL
4	NULL
(	NULL
4	NULL
)	NULL
layed	NULL
(	NULL
2	NULL
)	NULL
``	NULL
++++	NULL
,	NULL
replication	NULL
reached	NULL
the	NULL
wild-type	NULL
level	NULL
(	NULL
no	NULL
less	NULL
than	NULL
50	NULL
%	NULL
)	NULL
with	NULL
no	NULL
delay	NULL
or	NULL
an	NULL
unsubstantial	NULL
delay	NULL
compared	NULL
with	NULL
SIVmac239	NULL
in	NULL
all	NULL
experiments	NULL
;	NULL
slightly	NULL
delayed	NULL
,	NULL
replication	NULL
reached	NULL
wild-type	NULL
levels	NULL
2	NULL
to	NULL
3	NULL
days	NULL
later	NULL
than	NULL
SIV	NULL
mac239	NULL
;	NULL
delayed	NULL
,	NULL
replication	NULL
reached	NULL
wild-type	NULL
levels	NULL
>	NULL
4	NULL
days	NULL
later	NULL
than	NULL
SIVmac239	NULL
;	NULL
+++	NULL
,	NULL
replication	NULL
reached	NULL
the	NULL
wild-type	NULL
level	NULL
in	NULL
two	NULL
of	NULL
three	NULL
experiments	NULL
;	NULL
++	NULL
,	NULL
replication	NULL
reached	NULL
the	NULL
wild-type	NULL
level	NULL
in	NULL
one	NULL
of	NULL
three	NULL
experiments	NULL
;	NULL
+	NULL
,	NULL
replication	NULL
has	NULL
not	NULL
reached	NULL
the	NULL
wild-type	NULL
level	NULL
in	NULL
any	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

The	NULL
number	NULL
of	NULL
experiments	NULL
for	NULL
cach	NULL
mutant	NULL
with	NULL
each	NULL
cell	NULL
type	NULL
is	NULL
shown	NULL
in	NULL
parentheses	NULL
.	NULL

*	NULL
The	NULL
level	NULL
of	NULL
replication	NULL
of	NULL
this	NULL
mutant	NULL
in	NULL
macrophages	NULL
may	NULL
be	NULL
graded	NULL
as	NULL
between	NULL
++	NULL
and	NULL
+++	NULL
.	NULL

°	NULL
One	NULL
separate	NULL
stock	NULL
of	NULL
this	NULL
mutant	NULL
has	NULL
exhibited	NULL
wild-type	NULL
replication	NULL
in	NULL
CEMx174	NULL
cells	NULL
.	NULL

PCR	NULL
amplification	NULL
of	NULL
DNA	NULL
from	NULL
infected	NULL
cells	NULL
and	NULL
sequencing	NULL
of	NULL
five	NULL
separate	NULL
clones	NULL
through	NULL
the	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
have	NULL
not	NULL
shown	NULL
any	NULL
consistent	NULL
reversions	NULL
and	NULL
differences	NULL
from	NULL
``	NULL
normally	NULL
``	NULL
delayed	NULL
SIVmacMERsub	NULL
stSp1234	NULL
in	NULL
this	NULL
part	NULL
of	NULL
the	NULL
proviral	NULL
sequence	NULL
.	NULL

This	NULL
mutant	NULL
may	NULL
have	NULL
compensatory	NULL
mutations	NULL
elsewhere	NULL
in	NULL
the	NULL
genome	NULL
.	NULL

|	NULL
a	NULL
us	NULL
Tatamatar	NULL
Sam	NULL
)	NULL
atatm	NULL
aste	NULL
g927	NULL
TATAAATAT	NULL
ATATAA	NULL
|-tataaatat	NULL
HIV	NULL
NL4-3	NULL
LTR	NULL
9405	NULL
atataa	NULL
9425	NULL
9483	NULL
US	NULL
ATATAA	NULL
7	NULL
e	NULL
US	NULL
TATAAATAT	NULL
-	NULL
atataa	NULL
100	NULL
;	NULL
)	NULL
)	NULL
SIV	NULL
TRANSCRIPTION	NULL
AND	NULL
REPLICATION	NULL
WITHOUT	NULL
NF-	NULL
«	NULL
B	NULL
OR	NULL
Spi	NULL
3123	NULL
elements	NULL
,	NULL
we	NULL
constructed	NULL
an	NULL
equivalent	NULL
HIV	NULL
LTR	NULL
reporter	NULL
plasmid	NULL
with	NULL
65	NULL
bp	NULL
of	NULL
upstream	NULL
sequences	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
from	NULL
this	NULL
plasmid	NULL
also	NULL
reduced	NULL
SEAP	NULL
expression	NULL
to	NULL
background	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Thus	NULL
the	NULL
enhancer	NULL
element	NULL
present	NULL
upstream	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Spl	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
SIV	NULL
LTR	NULL
contains	NULL
no	NULL
equivalent	NULL
element	NULL
in	NULL
the	NULL
corresponding	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

We	NULL
also	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
LTR	NULL
mutations	NULL
on	NULL
the	NULL
SEAP	NULL
reporter	NULL
plasmid	NULL
activity	NULL
in	NULL
CEMx174	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
.	NULL

The	NULL
tat	NULL
gene	NULL
was	NULL
cotransfected	NULL
in	NULL
all	NULL
of	NULL
these	NULL
assays	NULL
.	NULL

As	NULL
in	NULL
COS-1	NULL
cells	NULL
,	NULL
elimination	NULL
of	NULL
the	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
sites	NULL
from	NULL
the	NULL
HIV-1	NULL
LTR	NULL
reduced	NULL
SEAP	NULL
activity	NULL
from	NULL
transfected	NULL
cells	NULL
to	NULL
background	NULL
levels	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
SIV-SEAP	NULL
plasmid	NULL
missing	NULL
the	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
retained	NULL
19	NULL
%	NULL
of	NULL
residual	NULL
activity	NULL
.	NULL

DISCUSSION	NULL
The	NULL
transcriptional	NULL
control	NULL
region	NULL
of	NULL
HIV-1	NULL
contains	NULL
two	NULL
binding	NULL
sites	NULL
for	NULL
NF-kB	NULL
and	NULL
three	NULL
sites	NULL
for	NULL
Sp1	NULL
(	NULL
12	NULL
)	NULL
.	NULL

These	NULL
sequences	NULL
quite	NULL
clearly	NULL
account	NULL
for	NULL
the	NULL
vast	NULL
majority	NULL
,	NULL
if	NULL
not	NULL
the	NULL
entirety	NULL
,	NULL
of	NULL
enhancer	NULL
activity	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

While	NULL
mutation	NULL
of	NULL
each	NULL
of	NULL
these	NULL
elements	NULL
individually	NULL
has	NULL
differential	NULL
effects	NULL
on	NULL
HIV-1	NULL
replication	NULL
on	NULL
different	NULL
cell	NULL
substrates	NULL
,	NULL
elimination	NULL
of	NULL
all	NULL
NF-kB	NULL
and	NULL
Spl	NULL
binding	NULL
sites	NULL
reduces	NULL
HIV-1	NULL
replication	NULL
to	NULL
below	NULL
detectable	NULL
levels	NULL
in	NULL
all	NULL
cell	NULL
types	NULL
tested	NULL
(	NULL
23	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
no	NULL
enhancer	NULL
elements	NULL
that	NULL
can	NULL
functionally	NULL
compensate	NULL
for	NULL
the	NULL
loss	NULL
of	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
are	NULL
present	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

The	NULL
transcriptional	NULL
control	NULL
regions	NULL
of	NULL
HIV-2	NULL
and	NULL
SIVmac	NULL
10093	NULL
SEAP	NULL
Si¥mac239	NULL
SEAP	NULL
SIVmac/HIV-1	NULL
TATA-box	NULL
SEAP	NULL
_	NULL
SiVmacANFKBASp1234	NULL
SIVmacANFKBASp1234/	NULL
SEAP	NULL
__	NULL
iv-1	NULL
TATA-box	NULL
SEAP	NULL
_	NULL
SiVmacAUSANFKkBASp1234	NULL
9611	NULL
SEAP	NULL
HIV-1	NULL
NL4-3	NULL
SEAP	NULL
_	NULL
HIV-1	NULL
NL4-3/SIV	NULL
TATA-box	NULL
SEAP	NULL
HIVANFKBASp123	NULL
HIVANFKBASp123/	NULL
SEAP	NULL
SIV	NULL
TATA-box	NULL
SEAP	NULL
_	NULL
HIVAUSANFKkBASp123	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
HIV	NULL
and	NULL
SIV	NULL
LTR	NULL
sequences	NULL
introduced	NULL
into	NULL
SEAP	NULL
reporter	NULL
constructs	NULL
.	NULL

Nucleotide	NULL
numbers	NULL
corresponding	NULL
to	NULL
the	NULL
inserted	NULL
and	NULL
deleted	NULL
proviral	NULL
sequences	NULL
are	NULL
shown	NULL
.	NULL

US	NULL
stands	NULL
for	NULL
upstream	NULL
U3	NULL
sequences	NULL
.	NULL

The	NULL
HIVANFxBASp123	NULL
plasmids	NULL
have	NULL
had	NULL
nucleotides	NULL
9425	NULL
to	NULL
9483	NULL
deleted	NULL
.	NULL

The	NULL
HIV	NULL
(	NULL
SIV	NULL
TATA-box	NULL
)	NULL
plasmids	NULL
have	NULL
had	NULL
nucleotides	NULL
9500	NULL
to	NULL
9509	NULL
changed	NULL
to	NULL
nucleotides	NULL
9948	NULL
to	NULL
9957	NULL
of	NULL
SIVmac239	NULL
.	NULL

The	NULL
viral	NULL
sequence	NULL
in	NULL
plasmid	NULL
HIVAUSANFxBASp123	NULL
starts	NULL
with	NULL
nucleotide	NULL
9484	NULL
.	NULL

Plasmid	NULL
STVmacANFxBASp1234	NULL
has	NULL
had	NULL
nucleotides	NULL
9876	NULL
to	NULL
9927	NULL
deleted	NULL
,	NULL
plasmid	NULL
SIVmac	NULL
(	NULL
HIV-1	NULL
TATA-box	NULL
)	NULL
has	NULL
had	NULL
nucleotides	NULL
9948	NULL
to	NULL
9957	NULL
changed	NULL
to	NULL
nucleotides	NULL
9500	NULL
to	NULL
9509	NULL
of	NULL
HIV	NULL
NL-43	NULL
,	NULL
and	NULL
the	NULL
viral	NULL
sequence	NULL
in	NULL
plasmid	NULL
SIVAUSANFKkBASp1234	NULL
starts	NULL
with	NULL
nucleotide	NULL
9928	NULL
.	NULL

The	NULL
designation	NULL
of	NULL
each	NULL
LTR-SEAP	NULL
construct	NULL
is	NULL
shown	NULL
.	NULL

Nucleotide	NULL
numbers	NULL
are	NULL
derived	NULL
from	NULL
reference	NULL
36	NULL
for	NULL
SIV	NULL
and	NULL
from	NULL
GenBank	NULL
(	NULL
4	NULL
)	NULL
for	NULL
HIV-1	NULL
NL-43	NULL
(	NULL
accession	NULL
number	NULL
M19921	NULL
)	NULL
.	NULL

3124	NULL
ILYINSKII	NULL
AND	NULL
DESROSIERS	NULL
J.	NULL
ViroL	NULL
.	NULL

A	NULL
I	NULL
»	NULL
~~	NULL
#	NULL
300	NULL
7	NULL
_|	NULL
HIV	NULL
(	NULL
SIV	NULL
TATA-box	NULL
)	NULL
250	NULL
€	NULL
p50	NULL
-	NULL
HIVANFKkBASp123	NULL
€	NULL
F	NULL
>	NULL
>	NULL
|	NULL
E	NULL
4	NULL
ke	NULL
)	NULL
]	NULL
s	NULL
.	NULL

F	NULL
|	NULL
'	NULL
E	NULL
poo	NULL
-	NULL
[	NULL
#	NULL
]	NULL
nivanrkBaSsp123	NULL
(	NULL
SIV	NULL
TATA-box	NULL
)	NULL
so	NULL
}	NULL
@	NULL
-	NULL
o	NULL
—-2001	NULL
HIVAUSANFKBASp123	NULL
£15904	NULL
s	NULL
1507	NULL
$	NULL
0	NULL
}	NULL
2	NULL
uso	NULL
|	NULL
>	NULL
100	NULL
&	NULL
,	NULL
}	NULL
2	NULL
100	NULL
€	NULL
100	NULL
-	NULL
219	NULL
8	NULL
$	NULL
00	NULL
3	NULL
&	NULL
50-	NULL
#	NULL
507	NULL
&	NULL
59-0	NULL
]	NULL
w	NULL
_	NULL
03	NULL
SEAP	NULL
activity	NULL
(	NULL
%	NULL
of	NULL
wild-type	NULL
)	NULL
Fold	NULL
transactivation	NULL
,	NULL
tat/no	NULL
tat	NULL
HIV-SEAP	NULL
SIV-SEAP	NULL
contain	NULL
one	NULL
binding	NULL
site	NULL
for	NULL
NF-kB	NULL
and	NULL
three	NULL
or	NULL
four	NULL
putative	NULL
binding	NULL
sites	NULL
for	NULL
Sp1	NULL
(	NULL
13	NULL
,	NULL
36	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
importance	NULL
of	NULL
these	NULL
elements	NULL
for	NULL
the	NULL
replication	NULL
of	NULL
HIV-2	NULL
and	NULL
SIVmac	NULL
has	NULL
not	NULL
to	NULL
our	NULL
knowledge	NULL
been	NULL
previously	NULL
investigated	NULL
.	NULL

However	NULL
,	NULL
transient	NULL
expression	NULL
assays	NULL
have	NULL
demonstrated	NULL
the	NULL
presence	NULL
of	NULL
enhancer	NULL
elements	NULL
upstream	NULL
of	NULL
the	NULL
single	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
element	NULL
in	NULL
HIV-2	NULL
and	NULL
SIVmac	NULL
and	NULL
that	NULL
these	NULL
additional	NULL
enhancer	NULL
elements	NULL
are	NULL
responsive	NULL
to	NULL
cell	NULL
activation	NULL
signals	NULL
(	NULL
5	NULL
,	NULL
25	NULL
,	NULL
26	NULL
,	NULL
37	NULL
)	NULL
.	NULL

The	NULL
main	NULL
objective	NULL
of	NULL
our	NULL
present	NULL
study	NULL
was	NULL
to	NULL
examine	NULL
the	NULL
relative	NULL
importance	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Spl	NULL
binding	NULL
elements	NULL
for	NULL
replication	NULL
of	NULL
SIVmac	NULL
in	NULL
primary	NULL
PBMCs	NULL
and	NULL
primary	NULL
SEAP	NULL
activity	NULL
(	NULL
%	NULL
of	NULL
witd-type	NULL
)	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
HIV	NULL
and	NULL
SIV	NULL
wild-type	NULL
and	NULL
mutant	NULL
LTR-SEAP	NULL
constructs	NULL
.	NULL

COS-1	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
HIV	NULL
LTR-SEAP	NULL
constructs	NULL
without	NULL
(	NULL
A	NULL
)	NULL
or	NULL
with	NULL
(	NULL
B	NULL
)	NULL
Tat	NULL
,	NULL
and	NULL
SEAP	NULL
activity	NULL
in	NULL
culture	NULL
supernatants	NULL
was	NULL
measured	NULL
16	NULL
to	NULL
18	NULL
h	NULL
later	NULL
.	NULL

Similar	NULL
experiments	NULL
were	NULL
also	NULL
performed	NULL
with	NULL
SIV	NULL
LTR-SEAP	NULL
constructs	NULL
without	NULL
(	NULL
C	NULL
)	NULL
and	NULL
with	NULL
(	NULL
D	NULL
)	NULL
Tat	NULL
.	NULL

The	NULL
activity	NULL
in	NULL
mutant-transfected	NULL
cells	NULL
is	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Tat	NULL
responsiveness	NULL
in	NULL
HIV	NULL
and	NULL
SIV	NULL
LTR-SEAP	NULL
constructs	NULL
.	NULL

The	NULL
results	NULL
are	NULL
summaries	NULL
of	NULL
three	NULL
to	NULL
six	NULL
independent	NULL
experiments	NULL
.	NULL

macrophages	NULL
of	NULL
rhesus	NULL
monkeys	NULL
.	NULL

A	NULL
collection	NULL
of	NULL
10	NULL
SIVmac	NULL
mutants	NULL
bearing	NULL
changes	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
elements	NULL
was	NULL
created	NULL
for	NULL
this	NULL
purpose	NULL
.	NULL

Since	NULL
interaction	NULL
and	NULL
cooperation	NULL
between	NULL
transcription	NULL
factors	NULL
may	NULL
greatly	NULL
influence	NULL
the	NULL
level	NULL
of	NULL
transcriptional	NULL
activity	NULL
(	NULL
24	NULL
,	NULL
34	NULL
,	NULL
35	NULL
)	NULL
,	NULL
both	NULL
deletion	NULL
and	NULL
substitution	NULL
mutations	NULL
were	NULL
employed	NULL
.	NULL

Unexpectedly	NULL
,	NULL
all	NULL
mutated	NULL
SIVs	NULL
replicated	NULL
with	NULL
kinetics	NULL
and	NULL
to	NULL
levels	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
parental	NULL
wild-type	NULL
virus	NULL
in	NULL
rhesus	NULL
monkey	NULL
PBMC	NULL
cultures	NULL
.	NULL

Even	NULL
mutant	NULL
virus	NULL
missing	NULL
all	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
sites	NULL
replicated	NULL
similarly	NULL
to	NULL
wild-type	NULL
virus	NULL
in	NULL
rhesus	NULL
monkey	NULL
PBMC	NULL
cultures	NULL
.	NULL

At	NULL
least	NULL
three	NULL
viruses	NULL
,	NULL
ANFkBA	NULL
Sp1234	NULL
,	NULL
substSp1234	NULL
,	NULL
and	NULL
ANFkBASp1	NULL
,	NULL
showed	NULL
a	NULL
consistent	NULL
delay	NULL
in	NULL
CEMx174	NULL
cells	NULL
.	NULL

The	NULL
terminally	NULL
differentiated	NULL
macrophage	NULL
represents	NULL
a	NULL
system	NULL
in	NULL
which	NULL
gene	NULL
expression	NULL
is	NULL
principally	NULL
dependent	NULL
on	NULL
con-stitutively	NULL
produced	NULL
transcription	NULL
factors	NULL
.	NULL

One	NULL
might	NULL
expect	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
lentiviral	NULL
transcription	NULL
in	NULL
these	NULL
cells	NULL
might	NULL
be	NULL
more	NULL
sensitive	NULL
to	NULL
specific	NULL
changes	NULL
in	NULL
individual	NULL
elements	NULL
.	NULL

In-deed	NULL
,	NULL
we	NULL
found	NULL
that	NULL
most	NULL
changes	NULL
in	NULL
Spl	NULL
binding	NULL
sites	NULL
had	NULL
a	NULL
dramatic	NULL
effect	NULL
on	NULL
SIV	NULL
replication	NULL
in	NULL
macrophages	NULL
.	NULL

In	NULL
partic-ular	NULL
,	NULL
Spl	NULL
substitution	NULL
mutations	NULL
which	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
SIV	NULL
replication	NULL
in	NULL
CEMx174	NULL
and	NULL
PBMC	NULL
cultures	NULL
severely	NULL
impaired	NULL
virus	NULL
replication	NULL
in	NULL
primary	NULL
rhesus	NULL
monkey	NULL
macrophages	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
had	NULL
little	NULL
impact	NULL
on	NULL
SIV	NULL
replication	NULL
in	NULL
voL	NULL
.	NULL

70	NULL
,	NULL
1996	NULL
180	NULL
I	NULL
HIV	NULL
NL-43	NULL
@	NULL
1607	NULL
HIV/argeUS	NULL
>	NULL
1	NULL
2	NULL
140	NULL
120	NULL
pe	NULL
I	NULL
HIVANFKBASp123	NULL
HIVANFKkBASp123/largeUS	NULL
SEAP	NULL
activity	NULL
(	NULL
%	NULL
of	NULL
the	NULL
wil	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
HIV/largeUS	NULL
LTR-SEAP	NULL
constructs	NULL
.	NULL

The	NULL
plasmids	NULL
HIV/largeUS	NULL
and	NULL
HIVANFkBASp123/largeUS	NULL
were	NULL
created	NULL
by	NULL
the	NULL
insertion	NULL
of	NULL
HIV	NULL
NL-43	NULL
nucleotides	NULL
9362	NULL
to	NULL
9404	NULL
into	NULL
plasmids	NULL
HIV	NULL
NL-43	NULL
and	NULL
of	NULL
HIV	NULL
LTR-SEAP	NULL
.	NULL

macrophages	NULL
.	NULL

The	NULL
SIV	NULL
macMER	NULL
mutant	NULL
with	NULL
point	NULL
mutations	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
did	NULL
not	NULL
show	NULL
any	NULL
growth	NULL
retardation	NULL
in	NULL
primary	NULL
rhesus	NULL
monkey	NULL
macrophages	NULL
,	NULL
and	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
deletion	NULL
mutant	NULL
was	NULL
only	NULL
marginally	NULL
delayed	NULL
in	NULL
these	NULL
cultures	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
in	NULL
direct	NULL
disagreement	NULL
with	NULL
those	NULL
reported	NULL
by	NULL
Bellas	NULL
et	NULL
al	NULL
.	NULL

(	NULL
2	NULL
)	NULL
,	NULL
who	NULL
found	NULL
profound	NULL
effects	NULL
of	NULL
the	NULL
NF-KB	NULL
site	NULL
for	NULL
replication	NULL
of	NULL
SIV	NULL
mac	NULL
in	NULL
primary	NULL
rhesus	NULL
monkey	NULL
alveolar	NULL
macrophages	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
a	NULL
cooperative	NULL
relationship	NULL
among	NULL
Sp1	NULL
sites	NULL
or	NULL
between	NULL
Sp1	NULL
sites	NULL
and	NULL
other	NULL
enhancer	NULL
elements	NULL
.	NULL

This	NULL
cooperation	NULL
appears	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
high-level	NULL
SIV	NULL
replication	NULL
in	NULL
unstimulated	NULL
alveolar	NULL
macrophages	NULL
.	NULL

The	NULL
relative	NULL
effects	NULL
of	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
elements	NULL
will	NULL
not	NULL
necessarily	NULL
apply	NULL
to	NULL
other	NULL
sources	NULL
of	NULL
monocytes/macrophages	NULL
.	NULL

The	NULL
results	NULL
of	NULL
transient	NULL
expression	NULL
assays	NULL
suggest	NULL
that	NULL
the	NULL
70	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
NF-kB	NULL
element	NULL
in	NULL
SIVmac	NULL
are	NULL
principally	NULL
responsible	NULL
for	NULL
the	NULL
surprisingly	NULL
high	NULL
replicative	NULL
capacity	NULL
of	NULL
ANFkBASp1234	NULL
in	NULL
primary	NULL
rhesus	NULL
monkey	NULL
PBMC	NULL
cultures	NULL
.	NULL

Our	NULL
results	NULL
with	NULL
transient	NULL
transfection	NULL
assays	NULL
are	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
of	NULL
enhancer	NULL
elements	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
NF-xB	NULL
binding	NULL
sites	NULL
in	NULL
SIVmac	NULL
and	NULL
HIV-2	NULL
(	NULL
5	NULL
,	NULL
25	NULL
,	NULL
26	NULL
,	NULL
37	NULL
)	NULL
.	NULL

We	NULL
additionally	NULL
report	NULL
that	NULL
this	NULL
enhancer	NULL
element	NULL
is	NULL
responsive	NULL
to	NULL
Tat	NULL
transactivation	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
novel	NULL
enhancer	NULL
element	NULL
,	NULL
not	NULL
present	NULL
in	NULL
HIV-1	NULL
,	NULL
can	NULL
apparently	NULL
allow	NULL
a	NULL
significant	NULL
level	NULL
of	NULL
SIV	NULL
transcription	NULL
and	NULL
replication	NULL
in	NULL
the	NULL
complete	NULL
absence	NULL
of	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
.	NULL

HIV	NULL
NL-43	NULL
100	NULL
HIVANFKBASp123	NULL
go	NULL
P	NULL
so	NULL
HIVAUSANFKBASp123	NULL
70	NULL
SIVmac239	NULL
SIVANFKBASp1234	NULL
SIVAUSANFKBASp1234	NULL
SEAP	NULL
activity	NULL
(	NULL
%	NULL
of	NULL
the	NULL
wild-type	NULL
)	NULL
HIV-SEAP	NULL
SIV-SEAP	NULL
FIG	NULL
.	NULL

10	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
LTR-SEAP	NULL
constructs	NULL
in	NULL
CEMx174	NULL
cells	NULL
.	NULL

Five	NULL
micrograms	NULL
of	NULL
SEAP	NULL
plasmid	NULL
and	NULL
2	NULL
pg	NULL
of	NULL
Tat	NULL
plasmid	NULL
were	NULL
used	NULL
for	NULL
each	NULL
transfection	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
are	NULL
the	NULL
average	NULL
of	NULL
duplicate	NULL
measurements	NULL
.	NULL

SIV	NULL
TRANSCRIPTION	NULL
AND	NULL
REPLICATION	NULL
WITHOUT	NULL
NF-	NULL
«	NULL
B	NULL
OR	NULL
Spi	NULL
3125	NULL
In	NULL
rhesus	NULL
monkeys	NULL
infected	NULL
with	NULL
a	NULL
SIV	NULL
mutant	NULL
with	NULL
a	NULL
182-bp	NULL
deletion	NULL
in	NULL
unique	NULL
nef	NULL
sequences	NULL
,	NULL
additional	NULL
nef	NULL
sequences	NULL
are	NULL
lost	NULL
over	NULL
time	NULL
,	NULL
including	NULL
nef	NULL
sequences	NULL
which	NULL
overlap	NULL
U3	NULL
(	NULL
22	NULL
)	NULL
.	NULL

However	NULL
,	NULL
particular	NULL
cis-acting	NULL
sequences	NULL
known	NULL
to	NULL
be	NULL
important	NULL
for	NULL
viral	NULL
replication	NULL
are	NULL
specifically	NULL
retained	NULL
.	NULL

These	NULL
include	NULL
the	NULL
polypurine	NULL
tract	NULL
,	NULL
known	NULL
to	NULL
be	NULL
important	NULL
for	NULL
reverse	NULL
transcription	NULL
,	NULL
and	NULL
U3	NULL
terminal	NULL
sequences	NULL
,	NULL
known	NULL
to	NULL
be	NULL
important	NULL
for	NULL
viral	NULL
DNA	NULL
integration	NULL
.	NULL

It	NULL
is	NULL
worth	NULL
noting	NULL
that	NULL
the	NULL
50	NULL
bp	NULL
of	NULL
sequences	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
NF-kB	NULL
element	NULL
,	NULL
which	NULL
correspond	NULL
to	NULL
the	NULL
novel	NULL
enhancer	NULL
element	NULL
,	NULL
are	NULL
also	NULL
uniformly	NULL
retained	NULL
(	NULL
22	NULL
)	NULL
.	NULL

While	NULL
multiple	NULL
mutations	NULL
over	NULL
a	NULL
300-bp	NULL
stretch	NULL
of	NULL
upstream	NULL
U3	NULL
sequences	NULL
(	NULL
US	NULL
)	NULL
were	NULL
previously	NULL
shown	NULL
not	NULL
to	NULL
affect	NULL
SIV	NULL
mac239	NULL
replication	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
(	NULL
18	NULL
)	NULL
,	NULL
these	NULL
mutations	NULL
did	NULL
not	NULL
involve	NULL
the	NULL
50	NULL
bp	NULL
of	NULL
sequence	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
containing	NULL
this	NULL
novel	NULL
enhancer	NULL
element	NULL
.	NULL

The	NULL
novel	NULL
enhancer	NULL
element	NULL
is	NULL
overlapped	NULL
and	NULL
contained	NULL
within	NULL
the	NULL
nef	NULL
reading	NULL
frame	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
novel	NULL
enhancer	NULL
element	NULL
,	NULL
our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
SIVmac	NULL
TATA	NULL
box	NULL
(	NULL
TATAAATAT	NULL
)	NULL
is	NULL
more	NULL
efficient	NULL
than	NULL
the	NULL
HIV-1	NULL
TATA	NULL
box	NULL
(	NULL
ATATAA	NULL
)	NULL
and	NULL
that	NULL
this	NULL
contributes	NULL
to	NULL
the	NULL
residual	NULL
transcriptional	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
binding	NULL
elements	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
also	NULL
shown	NULL
that	NULL
enlargement	NULL
of	NULL
the	NULL
HIV-1	NULL
TATA	NULL
box	NULL
may	NULL
compensate	NULL
for	NULL
other	NULL
mutations	NULL
in	NULL
the	NULL
TCE	NULL
(	NULL
20	NULL
,	NULL
39	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
increased	NULL
activity	NULL
of	NULL
the	NULL
SIVmac	NULL
TATA	NULL
sequences	NULL
appears	NULL
to	NULL
contribute	NULL
less	NULL
than	NULL
the	NULL
enhancer	NULL
elements	NULL
upstream	NULL
of	NULL
NF-KB	NULL
.	NULL

The	NULL
relative	NULL
importance	NULL
of	NULL
these	NULL
transcriptional	NULL
control	NULL
elements	NULL
in	NULL
SIVmac	NULL
can	NULL
be	NULL
evaluated	NULL
under	NULL
even	NULL
more	NULL
relevant	NULL
conditions	NULL
in	NULL
whole	NULL
animals	NULL
.	NULL

The	NULL
use	NULL
of	NULL
the	NULL
SIV	NULL
clone	NULL
for	NULL
these	NULL
constructions	NULL
will	NULL
allow	NULL
assessment	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
TCE	NULL
mutations	NULL
on	NULL
viral	NULL
replication	NULL
and	NULL
pathogenic	NULL
potential	NULL
in	NULL
vivo	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
differential	NULL
effects	NULL
of	NULL
these	NULL
mutations	NULL
in	NULL
macrophages	NULL
versus	NULL
lymphocytes	NULL
in	NULL
culture	NULL
will	NULL
allow	NULL
us	NULL
to	NULL
draw	NULL
correlations	NULL
regarding	NULL
which	NULL
is	NULL
more	NULL
predictive	NULL
of	NULL
the	NULL
effects	NULL
in	NULL
vivo	NULL
.	NULL

Such	NULL
experiments	NULL
are	NULL
in	NULL
progress	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Susan	NULL
Czajak	NULL
for	NULL
technical	NULL
assistance	NULL
,	NULL
Robert	NULL
Means	NULL
for	NULL
providing	NULL
HIV	NULL
and	NULL
SIV	NULL
LTR-SEAP	NULL
plasmids	NULL
,	NULL
Sabine	NULL
Lang	NULL
for	NULL
helpful	NULL
discussion	NULL
,	NULL
Prabhat	NULL
Sehgal	NULL
for	NULL
lung	NULL
lavages	NULL
,	NULL
and	NULL
Richard	NULL
Gaynor	NULL
for	NULL
the	NULL
suggestion	NULL
of	NULL
exchanging	NULL
TATA	NULL
boxes	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
PHS	NULL
grants	NULL
AI35365	NULL
,	NULL
AI25328	NULL
,	NULL
and	NULL
RRO0168	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Alcami	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Lain	NULL
de	NULL
Lera	NULL
,	NULL
L.	NULL
Folgueira	NULL
,	NULL
M.-A	NULL
.	NULL

Pedraza	NULL
,	NULL
J.-M.	NULL
Jacque	NULL
,	NULL
F.	NULL
Bachelerie	NULL
,	NULL
A.	NULL
R.	NULL
Noriega	NULL
,	NULL
R.	NULL
T.	NULL
Hay	NULL
,	NULL
D.	NULL
Harrich	NULL
,	NULL
R.	NULL
B.	NULL
Gaynor	NULL
,	NULL
J.-L.	NULL
Vire-lizier	NULL
,	NULL
and	NULL
F.	NULL
Arenzana-Seisdedos	NULL
.	NULL

1995	NULL
.	NULL

Absolute	NULL
dependence	NULL
on	NULL
B	NULL
responsive	NULL
elements	NULL
for	NULL
initiation	NULL
and	NULL
Tat-mediated	NULL
amplification	NULL
of	NULL
HIV	NULL
transcription	NULL
in	NULL
blood	NULL
CD4	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

14:1552-1560	NULL
.	NULL

2	NULL
.	NULL

Bellas	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
N.	NULL
Hopkins	NULL
,	NULL
and	NULL
Y.	NULL
Li	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
is	NULL
necessary	NULL
for	NULL
efficient	NULL
replication	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
of	NULL
macaques	NULL
in	NULL
primary	NULL
macrophages	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67	NULL
:	NULL
2908-2913	NULL
.	NULL

3	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1992	NULL
.	NULL

Functional	NULL
roles	NULL
for	NULL
the	NULL
TATA	NULL
promoter	NULL
and	NULL
enhancers	NULL
in	NULL
basal	NULL
and	NULL
Tat-induced	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:139-149	NULL
.	NULL

4	NULL
.	NULL

Bilofsky	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
and	NULL
C.	NULL
Burks	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
GenBank	NULL
genetic	NULL
sequence	NULL
data	NULL
bank	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:1861-1863	NULL
.	NULL

5	NULL
.	NULL

Clark	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
M.	NULL
C.	NULL
Hannibal	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Markovitz	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
peri-	NULL
«	NULL
B	NULL
site	NULL
mediates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
enhancer	NULL
activation	NULL
in	NULL
monocytes	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:4854-4862	NULL
.	NULL

6	NULL
.	NULL

Coffin	NULL
,	NULL
J.	NULL
M.	NULL
1990	NULL
.	NULL

Retroviridae	NULL
and	NULL
their	NULL
replication	NULL
,	NULL
p.	NULL
1437-1500	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
and	NULL
D.	NULL
M.	NULL
Knipe	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
.	NULL

7	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
1987	NULL
.	NULL

Use	NULL
of	NULL
eukaryotic	NULL
expression	NULL
technology	NULL
in	NULL
the	NULL
functional	NULL
analysis	NULL
of	NULL
cloned	NULL
genes	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

152:684-703	NULL
.	NULL

8	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

Regulatory	NULL
pathways	NULL
governing	NULL
HIV-1	NULL
replication	NULL
.	NULL

Cell	NULL
58:423-426	NULL
.	NULL

9	NULL
.	NULL

Desrosiers	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
A.	NULL
Hansen-Moosa	NULL
,	NULL
K.	NULL
Mori	NULL
,	NULL
D.	NULL
P.	NULL
Bouvier	NULL
,	NULL
N.	NULL
W.	NULL
King	NULL
,	NULL
M.	NULL
D.	NULL
Daniel	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
Ringler	NULL
.	NULL

1991	NULL
.	NULL

Macrophage-tropic	NULL
variants	NULL
of	NULL
SIV	NULL
are	NULL
3126	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

ILYINSKII	NULL
AND	NULL
DESROSIERS	NULL
associated	NULL
with	NULL
specific	NULL
AIDS-related	NULL
lesions	NULL
but	NULL
are	NULL
not	NULL
essential	NULL
for	NULL
the	NULL
development	NULL
of	NULL
AIDS	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

139:29-35	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
D.	NULL
Harrich	NULL
,	NULL
E.	NULL
Soultanakis	NULL
,	NULL
F.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
LTR	NULL
TATA	NULL
and	NULL
TAR	NULL
region	NULL
sequences	NULL
required	NULL
for	NULL
transcriptional	NULL
regulation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:765-778	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
F.	NULL
K.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1987	NULL
.	NULL

Interactions	NULL
of	NULL
cellular	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

63761-3770	NULL
.	NULL

Gaynor	NULL
,	NULL
R.	NULL
1992	NULL
.	NULL

Cellular	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

AIDS	NULL
6:347-363	NULL
.	NULL

Guyader	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Emerman	NULL
,	NULL
P.	NULL
Sonigo	NULL
,	NULL
F.	NULL
Clavel	NULL
,	NULL
L.	NULL
Montagnier	NULL
,	NULL
and	NULL
M.	NULL
Alizon	NULL
.	NULL

1987	NULL
.	NULL

Genome	NULL
organization	NULL
and	NULL
transactivation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
236:662-669	NULL
.	NULL

Harrich	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
Garcia	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
Gaynor	NULL
.	NULL

1990	NULL
.	NULL

TAR	NULL
independent	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
phorbol	NULL
ester	NULL
stimulated	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:4417-4423	NULL
.	NULL

Harrich	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
Garcia	NULL
,	NULL
F.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
J.	NULL
Gonzalez	NULL
,	NULL
and	NULL
R.	NULL
Gaynor	NULL
.	NULL

1989	NULL
.	NULL

Role	NULL
of	NULL
SP1-binding	NULL
domains	NULL
in	NULL
in	NULL
vivo	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63	NULL
:	NULL
2585-2591	NULL
.	NULL

Henderson	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
X.	NULL
Zou	NULL
,	NULL
and	NULL
K.	NULL
L.	NULL
Calame	NULL
.	NULL

1995	NULL
.	NULL

C/EBP	NULL
proteins	NULL
activate	NULL
transcription	NULL
from	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
macrophages/monocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:5337-5344	NULL
.	NULL

Higuchi	NULL
,	NULL
R.	NULL
,	NULL
B.	NULL
Krummel	NULL
,	NULL
and	NULL
R.	NULL
K.	NULL
Saiki	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
general	NULL
method	NULL
of	NULL
in	NULL
vitro	NULL
preparation	NULL
and	NULL
specific	NULL
mutagenesis	NULL
of	NULL
DNA	NULL
fragments	NULL
:	NULL
study	NULL
of	NULL
protein	NULL
and	NULL
DNA	NULL
interactions	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:7351-7367	NULL
.	NULL

Iyinskii	NULL
,	NULL
P.	NULL
O.	NULL
,	NULL
M.	NULL
D.	NULL
Daniel	NULL
,	NULL
M.	NULL
A.	NULL
Simon	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Lackner	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
role	NULL
of	NULL
upstream	NULL
U3	NULL
sequences	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus-induced	NULL
AIDS	NULL
in	NULL
rhesus	NULL
monkeys	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:5933-5944	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
J.	NULL
T.	NULL
Kadonaga	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1986	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
AIDS	NULL
retrovirus	NULL
promoter	NULL
by	NULL
the	NULL
cellular	NULL
transcription	NULL
factor	NULL
,	NULL
Sp1	NULL
.	NULL

Science	NULL
232:755-759	NULL
.	NULL

Kashanchi	NULL
,	NULL
F.	NULL
,	NULL
R.	NULL
Shibata	NULL
,	NULL
E.	NULL
K.	NULL
Ross	NULL
,	NULL
J.	NULL
N.	NULL
Brady	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1994	NULL
.	NULL

Second-site	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
revertants	NULL
of	NULL
replication-defective	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
:	NULL
effects	NULL
of	NULL
revertant	NULL
TATA	NULL
box	NULL
motifs	NULL
on	NULL
virus	NULL
infectivity	NULL
,	NULL
LTR-directed	NULL
expression	NULL
,	NULL
in	NULL
vitro	NULL
RNA	NULL
synthesis	NULL
,	NULL
and	NULL
binding	NULL
of	NULL
basal	NULL
transcription	NULL
factors	NULL
TFIID	NULL
and	NULL
TFIIA	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:3298-3307	NULL
.	NULL

Kawakami	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
Scheidereit	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
and	NULL
purification	NULL
of	NULL
a	NULL
human	NULL
immunoglobulin-enhancer-binding	NULL
protein	NULL
(	NULL
NF-xB	NULL
)	NULL
that	NULL
activates	NULL
transcription	NULL
from	NULL
a	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:4700-4704	NULL
.	NULL

Kirchhoff	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
W.	NULL
I.	NULL
Kestler	NULL
III	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1994	NULL
.	NULL

Upstream	NULL
U3	NULL
sequences	NULL
in	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
are	NULL
selectively	NULL
deleted	NULL
in	NULL
vivo	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
an	NULL
intact	NULL
nef	NULL
gene	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2031-2037	NULL
.	NULL

Leonard	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Parrott	NULL
,	NULL
A.	NULL
J.	NULL
Buckler-White	NULL
,	NULL
W.	NULL
Turner	NULL
,	NULL
E.	NULL
K.	NULL
Ross	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
are	NULL
not	NULL
required	NULL
for	NULL
virus	NULL
infectivity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4919-4924	NULL
.	NULL

Majello	NULL
,	NULL
B.	NULL
,	NULL
P.	NULL
DeLuca	NULL
,	NULL
G.	NULL
Hagen	NULL
,	NULL
G.	NULL
Suske	NULL
,	NULL
and	NULL
L.	NULL
Lania	NULL
.	NULL

1994	NULL
.	NULL

Different	NULL
members	NULL
of	NULL
the	NULL
Sp1	NULL
multigene	NULL
family	NULL
exert	NULL
opposite	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
HIV-1	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

22:4914-4921	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
Hannibal	NULL
,	NULL
V.	NULL
L.	NULL
Perez	NULL
,	NULL
C.	NULL
Gauntt	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
(	NULL
HIVs	NULL
)	NULL
:	NULL
a	NULL
specific	NULL
regulatory	NULL
element	NULL
in	NULL
HIV-2	NULL
responds	NULL
to	NULL
stimulation	NULL
of	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:9099-9102	NULL
.	NULL

Markovitz	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
J.	NULL
Smith	NULL
,	NULL
J.	NULL
Hilfinger	NULL
,	NULL
M.	NULL
C.	NULL
Hannibal	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
J.	NULL
ViroL	NULL
.	NULL

2	NULL
enhancer	NULL
is	NULL
dependent	NULL
on	NULL
purine	NULL
box	NULL
and	NULL
xB	NULL
regulatory	NULL
elements	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:5479-5484	NULL
.	NULL

26a.Means	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
R.	NULL
Desrosiers	NULL
.	NULL

Unpublished	NULL
observations	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

Mori	NULL
,	NULL
K.	NULL
,	NULL
D.	NULL
J.	NULL
Ringler	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1993	NULL
.	NULL

Restricted	NULL
replication	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
strain	NULL
239	NULL
in	NULL
macrophages	NULL
is	NULL
determined	NULL
by	NULL
eny	NULL
but	NULL
is	NULL
not	NULL
due	NULL
to	NULL
restricted	NULL
entry	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:2807-2814	NULL
.	NULL

Mori	NULL
,	NULL
K.	NULL
,	NULL
D.	NULL
J.	NULL
Ringler	NULL
,	NULL
T.	NULL
Kodama	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1992	NULL
.	NULL

Complex	NULL
determinants	NULL
of	NULL
macrophage	NULL
tropism	NULL
in	NULL
env	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:2067-2075	NULL
.	NULL

Moses	NULL
,	NULL
A.	NULL
V.	NULL
,	NULL
C.	NULL
Ibanez	NULL
,	NULL
R.	NULL
Gaynor	NULL
,	NULL
P.	NULL
Ghazal	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
role	NULL
of	NULL
long	NULL
terminal	NULL
repeat	NULL
control	NULL
elements	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
basal	NULL
and	NULL
Tat-mediated	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
primary	NULL
human	NULL
macrophages	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:298-307	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-712	NULL
.	NULL

Naidu	NULL
,	NULL
Y.	NULL
M.	NULL
,	NULL
H.	NULL
W.	NULL
Kestler	NULL
III	NULL
,	NULL
Y.	NULL
Li	NULL
,	NULL
C.	NULL
V.	NULL
Butler	NULL
,	NULL
D.	NULL
P.	NULL
Silva	NULL
,	NULL
D.	NULL
K.	NULL
Schmidt	NULL
,	NULL
C.	NULL
D.	NULL
Troup	NULL
,	NULL
P.	NULL
K.	NULL
Sehgal	NULL
,	NULL
P.	NULL
Sonigo	NULL
,	NULL
M.	NULL
D.	NULL
Daniel	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
infectious	NULL
molecular	NULL
clones	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
SIV	NULL
,	NULL
,	NULL
...	NULL
.	NULL
)	NULL

and	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
2	NULL
:	NULL
persistent	NULL
infection	NULL
of	NULL
rhesus	NULL
monkeys	NULL
with	NULL
molecularly	NULL
cloned	NULL
SIV	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:4691-4696	NULL
.	NULL

Parrott	NULL
,	NULL
C.	NULL
,	NULL
T.	NULL
Seidner	NULL
,	NULL
E.	NULL
Duh	NULL
,	NULL
J.	NULL
Leonard	NULL
,	NULL
T.	NULL
S.	NULL
Theodore	NULL
,	NULL
A.	NULL
Buckler-White	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1991	NULL
.	NULL

Variable	NULL
role	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
Sp1-binding	NULL
sites	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
replication	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:1414-1419	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Agranoff	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1994	NULL
.	NULL

Transcription	NULL
factor	NULL
AP-2	NULL
regulates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
gene	NULL
expression	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:6820-6823	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Agranoff	NULL
,	NULL
E.	NULL
Pascal	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
interaction	NULL
between	NULL
the	NULL
DNA-binding	NULL
domains	NULL
of	NULL
RelA	NULL
(	NULL
p63	NULL
)	NULL
and	NULL
Sp1	NULL
mediates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
gene	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

14:6570-6583	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
N.	NULL
L.	NULL
Edwards	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Agranoff	NULL
,	NULL
R.	NULL
M.	NULL
Schmid	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
cooperative	NULL
interaction	NULL
between	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
is	NULL
required	NULL
for	NULL
HIV-1	NULL
enhancer	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:3551-3558	NULL
.	NULL

Regier	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Desrosiers	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
complete	NULL
nucleotide	NULL
sequence	NULL
of	NULL
a	NULL
pathogenic	NULL
molecular	NULL
clone	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
6:1221-1231	NULL
.	NULL

Renjifo	NULL
,	NULL
B.	NULL
,	NULL
N.	NULL
A.	NULL
Speck	NULL
,	NULL
S.	NULL
Winandy	NULL
,	NULL
N.	NULL
Hopkins	NULL
,	NULL
and	NULL
Y.	NULL
Li	NULL
.	NULL

1990.	NULL
cis-Acting	NULL
elements	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
a	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64	NULL
:	NULL
3130-3134	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
location	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
II	NULL
(	NULL
HTLV-III/LAV	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Cell	NULL
41:813-823	NULL
.	NULL

Ross	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
A.	NULL
J.	NULL
Buckler-White	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
G.	NULL
Englund	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1991	NULL
.	NULL

Contribution	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
binding	NULL
motifs	NULL
to	NULL
the	NULL
replicative	NULL
capacity	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
:	NULL
distinct	NULL
patterns	NULL
of	NULL
viral	NULL
growth	NULL
are	NULL
determined	NULL
by	NULL
T-cell	NULL
types	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4350-4358	NULL
.	NULL

Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
P.	NULL
J.	NULL
Utz	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
J.	NULL
J.	NULL
Toole	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
241:202-205	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
T.	NULL
M.	NULL
Welsh	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1990	NULL
.	NULL

Differences	NULL
in	NULL
transcriptional	NULL
enhancers	NULL
of	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
response	NULL
to	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:4348-4354	NULL
.	NULL

Winandy	NULL
,	NULL
S.	NULL
,	NULL
B.	NULL
Renjifo	NULL
,	NULL
Y.	NULL
Li	NULL
,	NULL
and	NULL
N.	NULL
Hopkins	NULL
.	NULL

1992	NULL
.	NULL

Nuclear	NULL
factors	NULL
that	NULL
bind	NULL
two	NULL
regions	NULL
important	NULL
to	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:5216-5223	NULL
.	NULL

